Check for updates

OPEN ACCESS

EDITED BY Aldo Rocca, University of Molise, Italy

REVIEWED BY

Paulo Roberto Stevanato Filho, AC Camargo Cancer Center, Brazil Daniel Neureiter, Salzburger Landeskliniken, Austria

*CORRESPONDENCE Jiang-wei Xiao 🔯 xiaojiangwei2018@163.com

[†]These authors share first authorship

RECEIVED 01 June 2023 ACCEPTED 31 July 2023 PUBLISHED 06 September 2023

CITATION

Zeng D-x, Yang Z, Tan L, Ran M-n, Liu Z-l and Xiao J-w (2023) Risk factors for lateral pelvic lymph node metastasis in patients with lower rectal cancer: a systematic review and meta-analysis. *Front. Oncol.* 13:1219608. doi: 10.3389/fonc.2023.1219608

COPYRIGHT

© 2023 Zeng, Yang, Tan, Ran, Liu and Xiao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Risk factors for lateral pelvic lymph node metastasis in patients with lower rectal cancer: a systematic review and meta-analysis

De-xing Zeng^{1†}, Zhou Yang^{2†}, Ling Tan^{3†}, Meng-ni Ran⁴, Zi-lin Liu¹ and Jiang-wei Xiao^{1*}

¹Department of Gastrointestinal Surgery, Clinical Medical College and The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, China, ²Department of Gastrointestinal Surgery, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China, ³Department of Urology, People's Hospital Affiliated to Chongqing Three Gorges Medical College, Chongqing, China, ⁴Department of Pharmacy, Three Gorges Hospital Affiliated to Chongqing University, Chongqing, China

Background and objective: Lateral pelvic lymph node (LPLN) metastasis is one of the prominent reasons for local recurrence (LR) in patients with rectal cancer (RC). The evaluation criteria of lateral lymph node dissection (LLND) for patients in eastern (mainly in Japan) and western countries have been controversial. The aim of this study was to analyse the risk factors for LPLN metastasis in order to guide surgical methods.

Methods: We searched relevant databases (Embase (Ovid), Medline (Ovid), PubMed, Cochrane Library, and Web of Science) for articles published between 1 January 2000 and 05 October 2022 to evaluate the risk factors for LPLN metastasis in patients with RC in this meta-analysis.

Results: A total of 24 articles with 5843 patients were included in this study. The overall results showed that female sex, age <60 years, pretherapeutic CEA level >5 ng/ml, clinical T4 stage (cT4), clinical M1 stage (cM1), distance of the tumour from the anal verge (AV) <50 mm, tumour centre located below the peritoneal reflection (Rb), short axis (SA) of LPLN \geq 8 mm before nCRT, short axis (SA) of LPLN \geq 5 mm after nCRT, border irregularity of LPLN, tumour size \geq 50 mm, pathological T3-4 stage (pT3-4), pathological N2 stage (pN2), mesorectal lymph node metastasis (MLNM), lymphatic invasion (LI), venous invasion (VI), CRM (+) and poor differentiation were significant risk factors for LPLN metastasis (P <0.05).

Conclusion: This study summarized almost all potential risk factors of LPLN metastasis and expected to provide effective treatment strategies for patients with LRC. According to the risk factors of lateral lymph node metastasis, we can adopt different comprehensive treatment strategies. High-risk patients can

perform lateral lymph node dissection to effectively reduce local recurrence; In low-risk patients, we can avoid overtreatment, reduce complications and trauma caused by lateral lymph node dissection, and maximize patient survival and quality of life.

KEYWORDS

rectal cancer, lateral pelvic lymph node metastasis, risk factors, meta-analysis, LPLN

1 Introduction

Colorectal cancer (CRC) is the third most common malignant tumour in the world. In 2020, it was ranked as the fourth leading cause of cancer death, second to lung cancer (1), and its burden is estimated to increase by 60% to more than 2.2 million new cases and 1.1 million cancer deaths by 2030 (2).

Local recurrence (LR) of RC is still a serious clinical problem that is related to low survival and high incidence rates. It diffuses through the superior lymphatic drainage of the inferior mesenteric artery as well as the lateral lymphatic drainage of the internal iliac artery outside the rectum (3, 4). Lateral pelvic lymph node (LPLN) metastasis is considered the main cause of LR in patients with low rectal cancer (LRC) (5-7). Several studies verified that the incidence of LPLN metastasis in patients with LRC was approximately 15% (8), while the incidence of stages T3 and T4 exceeded 20% (9, 10). Klusters M et al. assumed that lymph and tumour cells wound flow into the LPLN system when the tumour is crushed during surgical resection. In addition, the LPLN system was left untouched during standard TME, and partial damage during rapid dissection of the lateral ligament led to lateral positive lymphatic residue. Finally, lymph converged in the presacral area and flowed into serum, which might have led to local tumour recurrence (11). It is urgent to find the relevant risk factors for LPLN metastasis. However, recent studies have shown that lateral recurrence has become the most common recurrence mode, accounting for up to 50%~82.7%. Lateral recurrence after rectal cancer surgery has been heavily discussed and is a barrier to prevention and treatment of colorectal surgery (6).

However, there has been no meta-analysis to clarify the risk factors for LPLN metastasis in patients with LRC to date. We

included all significantly relevant articles to compile this metaanalysis to further guide the treatment of rectal cancer patients with suspected LPLN metastasis. It can guide us to identify which patients with rectal cancer need lateral lymph node dissection to reduce the risk of local recurrence.

2 Materials and methods

2.1 Literature search

Studies published up to 05 October 2022 were identified by searching Embase (Ovid), Medline (Ovid), PubMed, Cochrane Library, and Web of Science. No regional restriction was imposed. Articles were confined to human studies published in English. The search algorithms consisted of Medical Subject Headings (MeSH) and free text terms, including the following: "Rectal cancer", "Lateral pelvic lymph node metastasis", and "risk factor". Eligible literature was identified by reading the included relevant articles.

2.2 Article selection

Inclusion criteria: (1) participants: rectal cancer patients with clinically suspected LPLN metastasis; (2) intervention: pathological examination confirmed positive metastasis of LPLN; (3) comparison: pathological examination confirmed negative metastasis of LPLN; (4) outcome measures: report at least one of the endpoints listed in Table 1; (5) study design: randomized controlled trials, prospective or retrospective cohort and case-control studies. Studies were excluded if: (1) they were reviews, case reports, conference articles or unrelated studies (the article did not contain rectal cancer, lymphatic metastasis, or risk factor analysis); (2) the metastatic lymph node was not LPLN; and (3) no outcome measures of interest were reported.

2.3 Outcomes of interest

We tried to screen all comparable data of the included articles as fully as possible. When a certain indicator contains data with more than 2 articles, it is considered as "Outcomes of Interest". The

Abbreviations: AV, anal verge; CIs, confidence intervals; cM1, clinical M1 stage; cN, clinical N stage; CRC, Colorectal cancer; ESGAR, the European Society of Gastrointestinal and Abdominal Radiology; LI, lymphatic invasion; LLND, lateral lymph node dissection; LPLN, Lateral pelvic lymph node; LR, local recurrence; LRC, low rectal cancer; MeSH, Medical Subject Headings; MLNM, mesorectal lymph node metastasis; MRA, middle rectal artery; MRI-EMVI, extramural venous invasion on MRI; NOS, Newcastle Ottawa Scale; ORs, Odds ratios; OSNA, one-step nucleic acid amplification; pN, pN stage; pN2, pathological N2 stage; pT3-4, pathological T3-4 stage; R1, positive circumferential margin; Rb, below the peritoneal reflection; RC, rectal cancer; SA, short axis; VI, venous invasion.

indicators were as follows: Sex, age, pretherapeutic CEA level (ng/ ml), border irregularity of LPLN, mixed signal intensity of LPLN, short axis of LPLN before CRT (mm), short axis of LPLN after CRT (mm), distance of the tumour from the AV (50 mm or 40 mm), tumour location, tumour size (mm), cT, cN, cM, pT, pN, LI, MLNM, VI, PI, CRM and differentiation.

2.4 Data extraction and outcome measures

Two authors (ZDX and TL) independently screened all the included studies and extracted the relevant data. Divergence of views was resolved through discussion between the authors. When consensus could not be reached, the third author (RMN) was

| TABLE 1 | Main | characteristics | of the | selected | studies. |
|---------|------|-----------------|--------|----------|----------|
| | | | | | |

| Reference | Journal | Country | Ν | LPLN (+) rate | Age | Operation method | Outcome |
|-----------------------|--|---------|------|------------------|--|---------------------|---|
| Abe 2022 (12) | World Journal of Surgical Oncology | Japan | 67 | 26.9% | LPLN(+): 66.5 (47-83) LPLN(-): 65 (33-78) | laparoscopy/open | 1, 3, 10a, 12, 13, 14, 15, 17 |
| Dev 2018 (13) | Indian Journal of Surgical Oncology | India | 43 | 20.9% | / | / | 1, 4, 7a, 9, 10a, 10b, 11a, 13, 17 |
| E. Agger 2021 (14) | International Journal of Colorectal Disease | Sweden | 344 | 8.7% | / | / | 1, 3, 10a, 10c, 14 |
| Fujita 2009 (15) | International Journal of Colorectal Disease | Japan | 210 | 22.4% | / | / | 1, 2, 4, 8, 9, 10a, 11a, 12, 13, 14, 15, 17 |
| Hiyoshi 2019 (16) | International Journal of Clinical Oncology | Japan | 78 | 11.5% | 62.8 (19-80) | laparoscopy/open | 1, 3, 4, 8, 10c, 13, 17 |
| Ishibe 2020 (17) | International Journal of Colorectal Disease | Japan | 458 | 15.5% | 63 (28-86) | open | 1, 4, 7b, 9, 13, 17 |
| Iwasa 2021 (18) | International Journal of Colorectal Disease | Japan | 102 | 19.6% | 64 (30-82) | / | 3, 4, 7a, 8, 10c, 16 |
| Kawai 2021 (19) | Disease Of The Colon & Rectum | Japan | 279 | 9.3% | 64 (32-86) | / | 1, 2, 6a, 7b, 10a, 10c |
| Kim 2007 (6) | Annals of Surgical Oncology | Korea | 366 | 6.6% | 57 (27-83) | / | 1, 4, 6b, 7a, 9, 10a, 16, 17 |
| Kim 2018 (20) | PLOS ONE | Korea | 57 | 40.4% | 57 (50–67) | / | 1, 4, 5a, 5b, 6a, 6b, 7a, 9, 10a, 11a, 11b, 12, 14, 15, 17 |
| Komori 2018 (21) | European Journal of Surgical Oncology | Japan | 328 | 7.3% | / | / | 1, 2, 6a, 7a, 8, 9, 11b, 17 |
| Lim 2013 (22) | International Journal of Colorectal Disease | Korea | 67 | 40.0% | / | / | 1, 8, 10a, 10b, 11a, 11b, 12, 15, 16, 17 |
| Malakorn 2019 (23) | Disease Of The Colon & Rectum | America | 64 | 51.6% | / | / | 1, 6b, 11a, 11b, 12, 15 |
| Nakanish 2020 (24) | Annls Surg Oncology | Japan | 247 | 28.7% | 60 (49-67) | / | 1, 4, 10a, 11a, 17 |
| Ogawa 2016 (25) | International Journal of Colorectal Disease | Japan | 394 | 21.3% | 64 (16-87) | / | 1, 10c, 11a, 13, 17 |
| Oh 2014 (26) | Annls Surg Oncology | Korea | 66 | 33.3% | 58.5 (31-82) | laparoscopy/open | 1, 9, 10a, 10b |
| Park 2018 (27) | journal of surgical research | Korea | 99 | 32.3% | / | 1 | 1, 4, 6b, 7a, 10a, 17 |
| Sekido 2019 (28) | Surgery Today | Japan | 60 | 20.0% | 60 (19–77) | 1 | 1, 2, 6b, 7b, 10a, 17 |
| Sugihara 2006 (7) | Dis Colon Rectum | Japan | 1977 | 6.5% | / | 1 | 1, 8, 11a, 12, 13, 14, 17 |
| Wang 2019 (29) | Colorectal Disease | China | 76 | 17.1% | 54.33 ± 10.03 | laparoscopy/open | 1, 2, 4, 6b, 7a, 17 |

(Continued)

TABLE 1 Continued

| Reference | Journal | Country | Ν | LPLN (+) rate | Age | Operation method | Outcome |
|-------------------|--|---------|-----|------------------|-------------|---------------------|---|
| Wang 2020 (30) | Journal of Gastrointestinal Surgery | Japan | 215 | 18.6% | / | laparoscopy/open | 1, 3, 4, 11a, 11b, 14, 17 |
| Wu 2007 (31) | World Journal of Gastroenterology | China | 96 | 14.6% | 65 (25-86) | / | 1, 2, 4, 9, 12, 14, 17 |
| Yang 2021 (32) | Techniques in Coloproctology | China | 77 | 28.6% | 54 (25-89) | laparoscopy/open | 1, 2, 3, 4, 6a, 7a, 10a, 10b, 11a, 11b, 17 |
| Zhou 2021 (33) | BMC Surgery | China | 73 | 20.5% | 55.8 ± 10.4 | laparoscopy/open | 1, 2, 4, 5a, 7a, 11a, 12, 14, 15, 17 |

LPLN, lateral pelvic lymph node; Outcome: 1 gender, 2 age, 3 preoperative therapy, 4 pre-therapy CEA (ng/ml), 5a border irregularity of LPLN, 5b mixed signal intensity of LPLN, 6a Short axis before CRT (mm), 6b Short diameter after CRT (mm), 7a distance of the tumor from the anal verge (50mm), 7b distance of the tumor from the anal verge (40mm), 8 tumor location, 9 tumor size (mm), 10a cT, 10b cN, 10c cM, 11a pT, 11b pN, 12 lymphatic invasion, 13 MLNM: mesorectal lymph node metastasis, 14 venous invasion, 15 perineural invasion, 16 CRM, 17 differentiation.

consulted, and a discussion ensued until a consensus was reached. The following relevant information was extracted from all the included studies: reference, journal, country, number of patients, LPLN (+) rate, age, operation method and endpoints.

2.5 Study quality assessment

The quality of the enrolled studies was evaluated by two authors independently using the Newcastle Ottawa Scale (NOS), with a maximum of nine points per study (34). Studies with a score <6 were considered low-quality studies and excluded. For this systematic review, we adhered to the Meta-analysis of Observational Studies guidelines and the Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) statement (35).

2.6 Statistical analysis

We used RevMan 5.4 software from the Cochrane Collaboration for all statistical analyses. Odds ratios (ORs) with 95% confidence intervals (CIs) were assessed to analyse dichotomous variables. p of Q test >0.1 and $I^2 < 50\%$ illustrated a lack of heterogeneity, and in this case, the pooled estimate was calculated by a fixed effects model. Otherwise, when p of Q test <0.1 or $I^2 >50\%$, a random effects model was adopted. A leave-one-out sensitivity analysis was performed by excluding one study back and forth to confirm that our results were not driven by any single trial. Publication bias was assessed by visual inspection of the symmetry of a funnel plot. The level of significance was defined as p <0.05 (test for heterogeneity was set at p <0.1).

3 Results

3.1 Study selection and characteristics

The flow chart for the inclusion of articles is shown in Figure 1. A total of 24 studies were eventually included in the quantitative

synthesis by screening databases through search strategies in advance (6, 7, 12–33). The baseline characteristics and lymph details of the studies are displayed in Table 1. A total of 24 retrospective articles with 5843 patients were included in this study, of which the LPLN-positive rate was between 6.5% and 51.6%. Most articles were reported in East Asia (12 in Japan, 5 in Korea, 4 in China and 1 in India), but 2 were reported in Western countries (1 in Sweden and the other in America). The NOS scores of the studies are displayed in Figure 2, and all studies scored 6 points or higher.

3.2 Outcomes of baseline characteristics

The outcomes are summarized in Figures 3A, B. For all outcomes, low statistical heterogeneity existed between the studies, and the fixed effects model was used. The pooled results showed a significantly higher risk of LPLN metastasis in females (OR: 1.28, 95% CI: 1.09-1.50, $I^2 = 18\%$, P =0.003) and age <60 years (OR: 1.41, 95% CI: 1.01-1.97, $I^2 = 5\%$, P =0.04).

3.3 Preoperative examination results

3.3.1 Pretherapy CEA level (ng/ml)

The outcome is listed in Figure 3C. No statistical heterogeneity existed between the studies; thus, the fixed effects model was used. Graphics demonstrated that a pretherapeutic CEA level >5 ng/ml was strongly associated with LPLN metastasis (OR: 1.55, 95% CI: 1.23-1.94, $I^2 = 0\%$, P =0.0002).

3.3.2 Tumour border and signal characteristics on MRI

The outcomes are listed in Figures 3D and S1. Pooled results revealed a significantly higher risk of LPLN metastasis with border irregularity on MRI (OR: 4.84, 95% CI: 2.09-11.21, $I^2 = 0\%$, P =0.0002). Regarding tumour signal characteristics, the random effects model was used due to obvious statistical heterogeneity, photographs seemed to not affect LPLN metastasis (OR: 3.98, 95% CI: 0.77-20.56, $I^2 = 76\%$, P =0.10).



3.3.3 SA of LPLN on MRI/CT (mm)

The outcomes are summarized in Figures 4A and S2. The fixed effects model was used because no statistical heterogeneity existed in the SA of LPLN \geq 5 mm after nCRT, while the random effects model was used because obvious statistical heterogeneity existed in the SA of LPLN \geq 8 mm before nCRT. Overall, the results showed that both SA of LPLN \geq 5 mm after nCRT (OR: 17.93, 95% CI: 10.02-32.07, I² = 0%, P <0.00001) and SA of LPLN \geq 8 mm before nCRT (OR: 9.33, 95% CI: 3.51-24.83, I² = 68%, P <0.00001) proved to be hazard factors for LPLN metastasis.

3.3.4 Tumour location and size

The outcomes are summarized in Figures 4B–D and 5A. The fixed effects model was used owing to low statistical heterogeneity. Overall, the results showed a significantly higher risk of LPLN metastasis in the distance of the tumour from the AV <50 mm (OR: 1.65, 95% CI: 1.17-2.31, $I^2 = 0\%$, P =0.004) or ≤40 mm (OR: 2.72, 95% CI: 1.74-4.26, $I^2 = 0\%$, P <0.0001), tumour centre located Rb (OR: 4.95, 95% CI: 3.18-7.71, $I^2 = 0\%$, P <0.00001), and tumour size ≥50 mm (OR: 1.65, 95% CI: 1.23-2.21, $I^2 = 39\%$, P =0.0009).

3.3.5 cTNM stage

The outcomes are summarized in Figures 5B, C and S3. The fixed effects model was used owing to low statistical heterogeneity. Pooled results revealed that both cT4 (OR: 1.56, 95% CI: 1.16-2.09, $I^2 = 15\%$, P =0.003) and cM1 (OR: 3.64, 95% CI: 2.31-5.73, $I^2 = 32\%$, P <0.00001) were hazard factors for LPLN metastasis. However, cN2-3 did not seem to affect LPLN metastasis (OR: 1.09, 95% CI: 0.61-1.93, $I^2 = 0\%$, P =0.77).

3.4 Postoperative examination results

3.4.1 pTN stage

The outcomes are summarized in Figures S4, 5. The random effects model was used because obvious statistical heterogeneity existed in pT stage, while the fixed effects model was used because no statistical heterogeneity existed in pN stage. Overall, the results showed that both pT3-4 (OR: 2.81, 95% CI: 1.83-4.30, $I^2 = 59\%$, P <0.00001) and pN2 (OR: 7.61, 95% CI: 4.88-11.85, $I^2 = 0\%$, P <0.00001) were conspicuous hazard factors for LPLN metastasis.

3.4.2 Invasion

The outcomes are summarized in Figures 5D, 6A, B and S6. Regarding LI, MLNM and VI, the fixed effects model was used owing to low statistical heterogeneity. Overall, the results showed a significantly higher risk of LPLN metastasis in LI (OR: 4.02, 95% CI: 2.98-5.43, $I^2 = 0\%$, P <0.00001), MLNM (OR: 6.20, 95% CI: 4.73-8.13, $I^2 = 0\%$, P <0.00001) and VI (OR: 2.52, 95% CI: 1.93-3.29, $I^2 = 18\%$, P <0.00001). While the random effects model was used because obvious statistical heterogeneity existed in the PI, photographs seemed to not affect LPLN metastasis (OR: 1.45, 95% CI: 0.86-2.45, $I^2 = 56\%$, P =0.17).

3.4.3 Differentiation and CRM

The outcomes are summarized in Figures 6C, D. The fixed effects model was used owing to low statistical heterogeneity. Overall, the results showed a significantly higher risk of LPLN metastasis in poor differentiation (OR: 3.34, 95% CI: 2.62-4.26, $I^2 = 22\%$, P <0.00001) and R1 (OR: 2.90, 95% CI: 1.13-7.40, $I^2 = 7\%$,

| Reference | Selection | Comparability | Outcome | Score |
|---------------|-----------|---------------|---------|-------|
| Abe 2022 | *** | * | *** | 7 |
| Dev 2018 | *** | ** | *** | 8 |
| E. Agger 2021 | *** | ** | *** | 8 |
| Fujita 2009 | *** | ** | *** | 8 |
| Hiyoshi 2019 | *** | ** | *** | 8 |
| Ishibe 2020 | *** | * * | ** | 7 |
| Iwasa 2021 | *** | ** | *** | 8 |
| Kawai 2021 | *** | * | ** | 6 |
| Kim 2007 | *** | ** | *** | 8 |
| Kim 2018 | *** | ** | *** | 8 |
| Komori 2018 | *** | * * | *** | 8 |
| Lim 2013 | *** | ** | ** | 7 |
| Malakorn 2019 | ** | ** | ** | 6 |
| Nakanish 2020 | *** | ** | *** | 8 |
| Ogawa 2016 | *** | ** | ** | 7 |
| Oh 2014 | *** | ** | *** | 8 |
| Park 2018 | *** | ** | ** | 7 |
| Sekido 2019 | *** | ** | *** | 8 |
| Sugihara 2006 | ** | ** | ** | 6 |
| Wang 2019 | *** | ** | *** | 8 |
| Wang 2020 | *** | ** | *** | 8 |
| Wu 2007 | * * * | ** | *** | 8 |
| Yang 2021 | *** | ** | *** | 8 |
| Zhou 2021 | *** | ** | * * * | 8 |

FIGURE 2

The NOS scores of studies. The * represent the various scores of the NOS scale.

P =0.03). The total valuable variables as possible risk factors for LPLN metastasis were summarized in Figure 7. The funnel plot of publication bias which included various indicators were listed in Figure 8.

4 Discussion

Surgical treatment is the main treatment for rectal cancer, in which radical resection and regional lymph node dissection are the key to success. The special drainage characteristics of rectal cancer lymph nodes determine the extent of lymph node dissection. The rectal lymphatic drainage area is distributed along the medial space of the obturator foramen of the internal iliac artery, and once metastasis occurs, it will spread upwards, laterally and downwards. It is worth noting that lateral lymph node metastasis is a metastatic pathway of low rectal cancer. Chemoradiotherapy has a poor effect and affects the prognosis of patients with rectal cancer. Previous literature has reported that LPLN metastasis is the main cause of LR in patients with LRC. Postoperative LR is a serious complication in patients with LRC that leads to pain, ureteral and intestinal obstruction, fistula and inflammation and significantly reduces the quality of life of patients. The prevention of LR is crucial because of the poor treatment effect when LR develops (36). Lateral lymph node metastasis is a common problem in the diagnosis and treatment of low rectal cancer, but there is still controversy between Eastern and Western scholars on whether TME should be combined with lateral lymph node dissection for middle and low rectal cancer (37). The studies and literature of Japanese scholars have confirmed that the effect of lateral lymph node dissection is affirmative, which can significantly reduce the local recurrence rate and significantly improve the 5-year survival rate. At present, lateral lymph node dissection has become a standard procedure in Japan. However, this procedure is not widely accepted in Western countries. The treatment for advanced rectal cancer in Europe and America is preoperative

| <u>Study of Subgrou</u> Abe.2022 Dev.2018 E. Agger.2021 Fujita.2009 Hiyosh.2019 Ishibe.2020 | 9 29 6 22 9 138 | Vents Total Weight 9 38 2.0% 3 21 0.8% | 1.45 [0.49, 4.29] | M-H, Fixed, 95% Cl |
|--|---|---|--|--------------------------------------|
| Kawai 2021 Kim 2007 Kim 2018 Komori 2018 Lim 2013 Malakorn 2019 Nakanishi. 2020 Ogawa 2016 Oh 2014 Park.2018 Sekido.2019 Sugihara.2006 Wang.2019 Wang.2019 Wang.2019 Wang.2020 Yu.2027 Yang.2021 Zhou.2021 Total (95% CI) Total events Heterogenetic CI | 17 64 5 30 32 153 10 98 7 119 8 24 6 107 19 32 16 31 32 85 31 133 7 19 12 41 4 20 62 757 6 35 10 67 8 50 10 67 8 50 10 67 8 50 10 41 5 30 2125 331 $y^2 = 26.70, (df = 22 (P = 1))$ | 21 206 6.0% 30 146 5.1% 4 48 1.0% 39 305 7.8% 16 181 3.8% 17 247 3.9% 18 221 4.2% 13 50 1.6% 17 33 3.0% 39 162 6.3% 19 162 6.3% 19 40 1.6% 19 57 4.3% 8 40 1.6% 67 1220 17.9% 8 40 1.6% 67 4.3% 8 40 1.6% 1220 3.7% 10 43 2.6% 3668 100.0% 468 | $\begin{array}{l} 2\ 5(\ 0\ 48,\ 0\ 10\ 0)\\ 0\ 61\ (0\ 27,\ 1\ 39)\\ 1\ 40\ (0\ 71,\ 29)\\ 1\ 40\ (0\ 71,\ 277)\\ 2\ 20\ (0\ 54,\ 856)\\ 1\ 40\ (0\ 71,\ 327)\\ 1\ 20\ (0\ 54,\ 856)\\ 1\ 40\ (0\ 54,\ 177)\\ 1\ 40\ (0\ 54,\ 177)\\ 1\ 40\ (0\ 54,\ 177)\\ 1\ 40\ (0\ 54,\ 177)\\ 1\ 40\ (0\ 54,\ 177)\\ 1\ 40\ (0\ 54,\ 177)\\ 1\ 40\ (0\ 54,\ 177)\\ 1\ 40\ (0\ 41,\ 360)\\ 0\ 33\ (0\ 35,\ 197)\\ 1\ 40\ (0\ 41,\ 380)\\ 0\ 33\ (0\ 35,\ 197)\\ 1\ 40\ (0\ 41,\ 380)\\ 0\ 33\ (0\ 35,\ 197)\\ 1\ 40\ (0\ 41,\ 380)\\ 0\ 33\ (0\ 35,\ 197)\\ 1\ 40\ (0\ 41,\ 380)\\ 0\ 33\ (0\ 35,\ 197)\\ 1\ 40\ (0\ 41,\ 380)\\ 0\ 33\ (0\ 35,\ 197)\\ 1\ 40\ (0\ 41,\ 380)\\ 0\ 33\ (0\ 35,\ 197)\\ 1\ 40\ (0\ 41,\ 380)\\ 0\ 33\ (0\ 35,\ 197)\\ 1\ 40\ (0\ 41,\ 380)\\ 0\ 33\ (0\ 35,\ 197)\\ 1\ 40\ (0\ 41,\ 380)\\ 0\ 43\ (0\ 35,\ 197)\\ 1\ 40\ (0\ 41,\ 380)\\ 0\ 43\ (0\ 35,\ 197)\\ 1\ 40\ (0\ 41,\ 380)\\ 0\ 40\ (0\ 32,\ 151)\\ 1\ 40\ (0\ 41,\ 380)\\ 0\ 40\ (0\ 32,\ 151)\\ 1\ 40\ (0\ 41,\ 380)\\ 0\ 40\ (0\ 41,\ 380)\\ 0\ 40\ (0\ 41,\ 41,\ 41)\\ 0\ 40\ 40\ 40\ 40\ 40\ 40\ 40\ 40\ 40\ $ | |
| Test for overall eff | n* = 26.70, df = 22 (P = iect: Z = 3.02 (P = 0.00) | | | 0.1 0.2 0.5 1 2 5 10 Female Male |
| Fujita 2009 Kawai 2021 Komori 2018 Sekido 2019 Wang 2019 Wu.2007 Yang 2021 Zhou.2021 Total (95% CI) Total events Heterogeneity: Ch | <60 p Events Total E 26 116 14 99 17 165 6 24 8 46 5 38 16 46 9 46 580 100 i ^P = 7.38, df = 7 (P = 0.4) ett Z = 201 (P = 0.04) | | Odds Ratio <u>M.H. Fixed, 95% C1</u> 0.90 (047, 1.72) 2.31 [1.02, 5.20] 2.56 [1.03, 6.35] 1.67 [047, 5.96] 1.67 [047, 5.96] 1.62 [0.47, 5.96] 2.22 [0.76, 6.53] 0.85 [0.27, 2.73] 1.41 [1.01, 1.97] | Odds Ratio M-H. Fixed, 95% Cl |
| С | | | Odda Batia | < 60 ≥60 |
| Dev.2018 Fuilts.2009 Hivoshi.2019 Ishibe.2020 Iwasa.2021 Kim.2017 Kim.2017 Nakanishi.2020 Park.2018 Wang.2019 Wang.2019 Wang.2019 Wu.2007 Yang.2021 Zhou.2021 Total (95% CI) Total events Heterogenetity. Ch | >5 p Events Total E 7 28 22 75 5 35 40 194 7 37 12 122 12 26 36 117 16 50 11 48 20 85 7 40 6 23 3 12 204 P= 6.50, df = 13 (P = 0 eet Z = 3.78 (P = 0.000 | | Odds Ratio MH, Fixed, 95% C1 2.17 (0.39, 12.06) 1.83 (0.94, 3.53) 1.83 (0.94, 3.53) 1.93 (0.40, 6.56) 1.90 (1.13, 3.20) 0.93 (0.34, 2.60) 2.11 (0.92, 4.85) 1.63 (0.55, 4.83) 1.21 (0.69, 2.09) 1.69 (0.95, 3.36) 1.48 (0.48, 2.55) 3.86 (0.79, 18.91) 1.49 (0.48, 3.63) 1.48 (0.48, 2.52) 1.36 (0.32, 5.81] 1.55 [1.23, 1.94] | Odds Ratio MH, Fixed, 95% Cl |
| D Study of Subgrou | | No <u>vents Total Weight</u> | Odds Ratio M-H, Fixed, 95% Cl | Odds Ratio M-H, Fixed, 95% Cl |
| kīm.2018 Zhou.2021 Total (95% CI) Total events Heterogeneily: Ch Testfor overail eff | 15 22 10 32 54 25 ₽ = 0.84, df = 1 (P = 0.3 ect: Z = 3.67 (P = 0.000 | 5 41 60.5% 76 100.0 % 13 36); I [#] = 0% | 7.23 [2.19, 23.88] 3.27 [0.99, 10.84] 4.84 [2.09, 11.21] | 0.05 0.2 1 5 20 Yes No |
| 3 | | r irregularity of | | |

neoadjuvant chemoradiotherapy (nCRT)+TME as a standard treatment strategy based on the explanation that LPLN is considered to be a systemic disease as well as unresectable by the TME procedure alone (38). In addition, several studies have authenticated that nCRT can reduce the rate of local recurrence (39, 40). However, Ogura et al. refuted that it is still a problem with the treatment of nCRT before TME and cleared the lower proportion of local recurrence when TME was combined with LLND (41).

In recent years, on account of recognition of local disease rather than a systemic disease about LPLN (8, 42, 43), the Japanese Society for Cancer of the Colon and Rectum recommends the LLND procedure for advanced LRC, especially located below the peritoneal reflection (Rb), which is able to reduce the rate of LPLN metastasis (44), but complications such as longer operation time, higher blood loss and sexual dysfunction occur sequentially (8, 45–47). Consequently, the TME+LLND group was compared with the TME+nCRT group, and Kusters et al. found that the local



located Rb.

recurrence rate in both groups was lower than that of the TME alone group, although there was no significant difference (48). In contrast, J.S. Williamson et al. supported the point of views that LLND, especially internal iliac lymph node metastasis, should be considered a resectable local disease and that enlarged lymph nodes that do not respond to nCRT should be surgically dissected (49).

We performed a meta-analysis to identify the risk factors for LPLN metastasis and to provide a more scientific and accurate evaluation index for lateral lymph node dissection. Our results showed that female sex, age <60 years, pretherapeutic CEA level >5 ng/ml, cT4, cM1, distance of the tumour from the AV <50 mm, tumour centre located Rb, SA of LPLN ≥8 mm before nCRT, SA of LPLN ≥5 mm after nCRT, border irregularity of LPLN, tumour size

 \geq 50 mm, pT3-4, pN2, MLNM, LI, VI, CRM (+) and poor differentiation were risk factors for LPLN metastasis.

Similar to previous studies (42, 50, 51), our results showed that female sex was independently associated with LPLN metastasis, potentially owing to the anatomical difference between the male and female pelvis (52). Age <60 years was risk factor as well, because younger patients had the higher basal metabolic rate, and the faster the tumor progression, the higher rate of LPLN metastasis. In addition, a pretherapeutic CEA level >5 ng/ml was associated with LPLN metastasis as well.Elevated CEA levels often indicate a later tumour stage and a greater risk of lateral lymph node metastasis. Similarly, tumour size \geq 50 mm was related to LPLN metastasis because the larger the tumour diameter, the greater the

| Study of Subgroup | ≥50 Evente Total | <50 Events Total Wei | Odds Ratio aht M-H, Fixed, 95% CI | Odds Ratio M-H, Fixed, 95% Cl |
|---|---|---|--|---|
| Dev.2018 | Events Total 7 26 | | 1mt M-H, Fixed, 95% CI 5% 2.76 [0.50, 15.29] | |
| Fujita.2009 | 25 106 | 22 104 24. | | |
| Ishibe.2020 | 52 244 | 19 214 22. | | |
| Kim.2007 | 9 172 | 15 294 14. | | |
| Kim.2018 | 7 18 | | 3% 0.91 [0.29, 2.87] | |
| Komori.2018 | 15 168 | 9 160 11. | | |
| Oh.2014 | 8 27 | 14 39 11. | | |
| Wu.2007 | 10 40 | | 6% 4.33 [1.25, 15.03] | |
| | | | | |
| Total (95% CI) | 801 | 923 100 | 0% 1.65 [1.23, 2.21] | ◆ |
| Total events | 133 | 101 | | |
| Heterogeneity: Chi ² : | = 11.51, df = 7 (P = | = 0.12); I ² = 39% | | |
| Test for overall effec | t: Z = 3.34 (P = 0.0 | 1009) | | 0.1 0.2 0.5 1 2 5 10 ≥50 <50 |
| | | | | |
| в | -74 | -73.3 | Odda Datia | |
| | cT4 Evente Total | cT2-3 Evente Tetal Mei | Odds Ratio | Odds Ratio M-H, Fixed, 95% Cl |
| Study or Subgroup | | | ght M-H, Fixed, 95% Cl | |
| Abe.2022 | 10 22 | | 3% 3.85 [1.24, 11.99] | |
| Dev.2018 | 6 19 | | 7% 3.23 [0.69, 15.21] | |
| E. Agger.2021 | 12 117 | | 4% 1.33 [0.62, 2.86] | |
| Fujita.2009 Kawai 2021 | 12 43 | | 5% 1.46 [0.68, 3.13] | |
| Kawai.2021 Kim 2007 | 4 22 | | 2% 2.37 [0.74, 7.63] | |
| Kim.2007 | 2 12 | | 8% 3.02 [0.62, 14.63] | |
| Kim.2018 | 2 11 | | 9% 0.26 (0.05, 1.36) 8% 0.40 (0.02, 8.44) | |
| Lim.2013 | 13 24 | | 6% 2.43 [0.92, 6.41] | |
| Nakanishi.2020 | 11 39 | | 3% 0.97 [0.45, 2.07] | |
| Oh.2014 | 2 7 | | 5% 0.78 [0.14, 4.38] | |
| Park.2018 | 58 | | 4% 3.95 [0.88, 17.71] | |
| Sekido.2019 | 2 5 | | 5% 3.00 [0.44, 20.38] | |
| Yang.2021 | 8 24 | 14 53 8 | 7% 1.39 [0.49, 3.96] | · · · · · · · · · · · · · · · · · · · |
| T-4-1 (072) OD | | | | |
| Total (95% CI) | 353 | 1644 100 | 0% 1.56 [1.16, 2.09] | |
| Total events | 89 | 279 | | |
| Heterogeneity: Chi ² | | | | 0.1 0.2 0.5 1 2 5 10 |
| Test for overall effec | 1. ∠ = 2.94 (F = 0.0 | 103) | | cT4 cT2-3 |
| | | | | |
| С | | | | |
| | cM1 | cM0 | Odds Ratio | Odds Ratio |
| | Events Total | | ht M-H, Fixed, 95% Cl | M-H, Fixed, 95% Cl |
| Study or Subgroup | | | 0. 1.7710.07.40.401 | |
| E. Agger.2021 | 12 52 | 18 292 27. | | - |
| E. Agger.2021 Hiyoshi.2019 | 5 13 | 4 65 5 | % 9.53 [2.11, 43.03] | |
| E. Agger.2021 Hiyoshi.2019 Iwasa.2021 | 5 13 3 11 | 4 65 5 17 91 17.: | % 9.53 [2.11, 43.03] % 1.63 [0.39, 6.81] | |
| E. Agger.2021 Hiyoshi.2019 | 5 13 | 4 65 5 | % 9.53 [2.11, 43.03] % 1.63 [0.39, 6.81] | |
| E. Agger.2021 Hiyoshi.2019 Iwasa.2021 | 5 13 3 11 | 4 65 5 17 91 17.: | % 9.53 [2.11, 43.03] % 1.63 [0.39, 6.81] % 0.36 [0.02, 6.31] | |
| E. Agger.2021 Hiyoshi.2019 Iwasa.2021 Kawai.2021 Ogawa.2016 | 5 13 3 11 0 12 15 32 | 4 65 5. 17 91 17. 26 266 15. 69 420 34. | % 9.53 [2.11, 43.03] % 1.63 [0.39, 6.81] % 0.36 [0.02, 6.31] % 4.49 [2.14, 9.41] | |
| E. Agger.2021 Hiyoshi.2019 Iwasa.2021 Kawai.2021 Ogawa.2016 Total (95% CI) | 5 13 3 11 0 12 15 32 120 | 4 65 5. 17 91 17. 26 266 15. 69 420 34. 1134 100. | % 9.53 [2.11, 43.03] % 1.63 [0.39, 6.81] % 0.36 [0.02, 6.31] % 4.49 [2.14, 9.41] | |
| E. Agger.2021 Hiyoshi.2019 Iwasa.2021 Kawai.2021 Ogawa.2016 Total (95% CI) Total events | 5 13 3 11 0 12 15 32 120 35 | 4 65 5. 17 91 17. 26 266 15. 69 420 34. 1134 100. 134 | % 9.53 [2.11, 43.03] % 1.63 [0.39, 6.81] % 0.36 [0.02, 6.31] % 4.49 [2.14, 9.41] | |
| E. Agger.2021 Hiyoshi.2019 Iwasa.2021 Kawai.2021 Ogawa.2016 Total (95% CI) Total events Heterogeneity: Chi ² : | 5 13 3 11 0 12 15 32 120 35 = 5.90, df = 4 (P = | 4 65 5. 17 91 17. 26 266 15. 69 420 34. 1134 100. 134 0.21); I² = 32% | % 9.53 [2.11, 43.03] % 1.63 [0.39, 6.81] % 0.36 [0.02, 6.31] % 4.49 [2.14, 9.41] | |
| E. Agger.2021 Hiyoshi.2019 Iwasa.2021 Kawai.2021 Ogawa.2016 Total (95% CI) Total events | 5 13 3 11 0 12 15 32 120 35 = 5.90, df = 4 (P = | 4 65 5. 17 91 17. 26 266 15. 69 420 34. 1134 100. 134 0.21); I² = 32% | % 9.53 [2.11, 43.03] % 1.63 [0.39, 6.81] % 0.36 [0.02, 6.31] % 4.49 [2.14, 9.41] | 0.005 0.1 cml cm0 |
| E. Agger.2021 Hiyoshi.2019 Iwasa.2021 Kawai.2021 Ogawa.2016 Total (95% CI) Total events Heterogeneity: Chi ² : | 5 13 3 11 0 12 15 32 120 35 = 5.90, df = 4 (P = | 4 65 5. 17 91 17. 26 266 15. 69 420 34. 1134 100. 134 0.21); I² = 32% | % 9.53 [2.11, 43.03] % 1.63 [0.39, 6.81] % 0.36 [0.02, 6.31] % 4.49 [2.14, 9.41] | |
| E, Agger.2021 Hiyoshi.2019 Iwasa.2021 Kawai.2021 Ogawa.2016 Total (95% CI) Total events Heterogeneity: Chi ^a : Test for overall effec | 5 13 3 11 0 12 15 32 120 35 = 5.90, df = 4 (P = | 4 65 5. 17 91 17. 26 266 15. 69 420 34. 1134 100. 134 0.21); I² = 32% | % 9.53 [2.11, 43.03] % 1.63 [0.39, 6.81] % 0.36 [0.02, 6.31] % 4.49 [2.14, 9.41] | |
| E. Agger.2021 Hiyoshi.2019 Iwasa.2021 Kawai.2021 Ogawa.2016 Total (95% CI) Total events Heterogeneity: Chi ² : | 5 13 3 11 0 12 15 32 120 35 = 5.90, df = 4 (P = t Z = 5.59 (P < 0.0 | 4 65 6. 17 91 17: 26 266 15: 89 420 34: 1134 100. 134 0.21); I ⁺ = 32% 0001) | 9.53 [2.11, 43.03] 1.63 [0.39, 6.81] 0.36 [0.02, 6.31] 4.49 [2.14, 9.41] 3.64 [2.31, 5.73] | cM1 cM0 |
| E, Agger.2021 Hiyoshi.2019 Iwasa.2021 Kawai.2021 Ogawa.2016 Total (95% CI) Total events Heterogeneity: Chi ^a : Test for overall effect | 5 13 3 11 0 12 15 32 120 35 = 5.90, df = 4 (P = t Z = 5.59 (P < 0.0 | 4 65 5. 17 91 17. 26 266 15. 69 420 34. 134 100. 134 0.21); I ⁺ = 32% 0001) | 9.53 [2.11, 43.03] 1.63 [0.39, 6.81] 0.36 [0.02, 6.31] 4.49 [2.14, 9.41] 3.64 [2.31, 5.73] | cM1 cM0 Odds Ratio |
| E. Agger.2021 Hyossh.2019 Hwasa.2021 Kawai.2021 Ogawa.2016 Total (95% CI) Total events Heterogeneity: ChP Test for overall effec D | 5 13 3 11 0 12 15 32 120 35 5 90, df = 4 (P = t Z = 5.59 (P < 0.0 LI (+) Events Total | 4 65 5. 17 91 17: 26 266 15: 69 420 34: 1134 100. 134 0.21); P = 32% 0001) Events Total Weigl | 9.53 [2.11, 43.03] 1.63 [0.39, 6.81] 0.36 [0.02, 6.31] 4.49 [2.14, 9.41] 3.64 [2.31, 5.73] Odds Ratio M.H. Fixed, 95% CI | cM1 cMO |
| E. Agger.2021 Hiyoshi.2019 Iwasa.2021 Kawai.2021 Ogawa.2016 Total (95% CI) Total events Heterogeneity: Chi≆: Test for overall effec D <u>Study or Subgroup</u> Abe.2022 | 5 13 3 11 0 12 15 32 120 35 5 5.90, df = 4 (P = t Z = 5.59 (P < 0.0 L1 (+) <u>Events Total</u> 5 11 | 4 65 5. 17 91 17: 26 266 15: 69 420 34: 134 100. 134 0.21); I ⁺ = 32% 0001) LU (-) Events Total Weight 13 56 4.5' | 9.53 [2.11, 43.03] 1.63 [0.39, 6.81] 0.36 [0.2, 6.31] 4.49 [2.14, 9.41] 3.64 [2.31, 5.73] 0.dds Ratio t. M-H, Fixed, 95% CI 2.76 [0.72, 10.52] | cM1 cM0 Odds Ratio |
| E. Agger.2021 Hiyoshi.2019 Iwasa.2021 Kawai.2021 Ogawa.2016 Total (95% CI) Total events Heterogeneity: Chi ^P : Test for overall effect D <u>Study or Subgroup</u> Abe.2022 Fujita.2009 | 5 13 3 11 0 12 15 32 120 35 5 59 (P < 0.0 L1 (+) <u>Events Total</u> 5 11 30 77 | 4 65 5. 17 91 17: 26 266 15: 69 420 34: 1134 100. 134 0. 021); P= 32% 0001) L1 (-) <u>Events Total Weinli</u> 13 56 4.5' 17 133 14.8' | 9.53 [2.11, 43.03] 1.63 [0.39, 6.81] 0.36 [0.2, 6.31] 4.49 [2.14, 9.41] 3.64 [2.31, 5.73] 0.364 [2.31, 5.73] 0.44 [2.31, 5.73] | cM1 cM0 Odds Ratio |
| E. Agger.2021 Hyoshi.2019 Hwasa.2021 Kawai.2021 Ogawa.2016 Total events Heterogeneity: ChP*: Test for overall effect D Study or Subgroup Abe.2022 Fujita.2009 Kim.2018 | $\begin{array}{cccc} 5 & 13 \\ 3 & 11 \\ 0 & 12 \\ 15 & 32 \end{array}$ $\begin{array}{c} 120 \\ 35 \\ = 5.90, df = 4 \ (P = \\ LZ = 5.59 \ (P < 0.0 \\ \hline \\ $ | 4 65 6. 17 91 17: 26 266 15: 69 420 34: 1134 100. 134 0.21); I [*] = 32% 0001) Events Total Weigl 13 56 4.5; 17 133 14.8° 9 32 6.7° | 9.53 [2.11, 43.03] 1.63 [0.39, 6.81] 0.36 [0.02, 6.31] 4.49 [2.14, 9.41] 3.64 [2.31, 5.73] 0.04ds Ratio t. M-H, Fixed, 95% CI 4.36 [2.20, 8.64] 3.25 [2.08, 9.64] 3.25 [2.08, 9.64] | cM1 cM0 Odds Ratio |
| E, Agger.2021 Hiyoshi.2019 Iwasa.2021 Kawai.2021 Ogawa.2016 Total (95% CI) Total events Heterogeneity: Chi ² : Test for overall effec D <u>Study or Subgroup</u> Abe.2022 Fujita.2009 Kim.2018 Lim.2013 | 5 13 3 11 0 12 15 32 120 35 5.50, df = 4 (P = t Z = 5.59 (P < 0.0 LU (+) <u>Events Total</u> 5 11 30 77 14 25 8 13 | 4 65 5. 17 91 17: 26 266 15: 69 420 34: 134 100. 134 000. 134 000. 134 000. 134 134 100. 134 000. 134 000. 135 400. 137 133 14.8 9 32 6.7' 24 69 5.7' | 9.53 [2.11, 43.03] 1.63 [0.39, 6.81] 0.36 [0.2, 6.31] 4.49 [2.14, 9.41] 3.64 [2.31, 5.73] 0.449 [2.14, 9.41] 3.64 [2.31, 5.73] 2.76 [0.72, 10.52] 4.36 [2.20, 8.64] 3.25 [1.08, 9.80] 3.00 [0.88, 10.18] | cM1 cM0 Odds Ratio |
| E. Agger.2021 Hiyoshi.2019 Iwasa.2021 Kawai.2021 Ogawa.2016 Total (95% CI) Total events Heterogeneity: Chi ^p : Test for overall effect D <u>Study or Subgroup</u> Abe.2022 Fujita.2009 Kim.2018 Lim.2013 Malakom.2019 | 5 13 3 11 0 12 15 32 120 35 5 59 (P < 0.0 L1 (+) Events Total 5 11 30 77 14 25 8 13 8 13 16 22 | 4 65 5. 17 91 17: 26 266 15: 69 420 34: 1134 100. 134 0. 0.21); P = 32% 0001) Events Total Weight 13 56 4.5 17 133 14.8' 9 32 6.7' 24 69 5.7' 17 42 6.2' | 9.53 [2.11, 43.03] 1.63 [0.39, 6.81] 0.36 [0.02, 6.31] 4.49 [2.14, 9.41] 3.64 [2.31, 5.73] 0.449 [2.14, 9.41] 3.64 [2.31, 5.73] 4.49 [2.10, 50% CI 4.76 [0.72, 10.52] 4.36 [2.20, 8.64] 3.25 [1.08, 9.80] 3.00 [0.88, 10.18] 3.92 [1.28, 12.05] | cM1 cM0 Odds Ratio |
| E. Agger.2021 Hyoshi.2019 Hwasa.2021 Kawai.2021 Ogawa.2016 Total events Heterogeneity: ChP Test for overall effec D Study of Subgroup Abe.2022 Fujita.2009 Kim.2018 Lim.2018 Lim.2019 Ogawa.2016 | $\begin{array}{cccc} 5 & 13 \\ 3 & 11 \\ 0 & 12 \\ 15 & 32 \end{array}$ $\begin{array}{c} 120 \\ 35 \\ = 5.90, df = 4 \ (P = \\ t \ Z = 5.59 \ (P < 0.0 \\ \end{array}$ $\begin{array}{c} LI \ (+) \\ \hline \hline Events \ Total \\ 5 \ 11 \\ 30 \ 77 \\ 14 \ 25 \\ 8 \ 13 \\ 16 \ 22 \\ 7 \ 282 \end{array}$ | L1(-) Events Total Weig1 13 56 4.5 69 420 34: 1134 100. 134 0.21); P = 32% 0001) Events Total Weig1 13 56 4.5 17 133 14.8 9 32 6.7 24 69 5.7 17 42 6.7 17 42 6.7 17 42 6.7 | 9.53 [2.11, 43.03] 1.63 [0.39, 6.81] 0.36 [0.2, 6.31] 4.49 [2.14, 9.41] 3.64 [2.31, 5.73] 3.64 [2.31, 5.73] 2.76 [0.72, 10.52] 4.36 [2.20, 8.64] 3.26 [1.08, 9.80] 3.00 [0.88, 10.18] 3.92 [1.28, 12.05] 4.12 [2.37, 8.60] | cM1 cM0 Odds Ratio |
| E. Agger.2021 Hiyoshi.2019 Iwasa.2021 Kawai.2021 Ogawa.2016 Total (95% CI) Total events Heterogeneity: Chi ^a : Test for overall effect D <u>Study or Subgroup</u> Abe.2022 Fujita.2009 Kim.2018 Lim.2013 Malakom.2019 Ogawa.2016 | $\begin{array}{cccc} 5 & 13 \\ 3 & 11 \\ 0 & 12 \\ 15 & 32 \end{array}$ $\begin{array}{c} 120 \\ 35 \\ = 5.90, df = 4 \ (P = \\ t \ Z = 5.59 \ (P < 0.0 \\ \hline \\ $ | 4 65 5. 17 91 17: 26 266 15: 69 420 34: 134 100. 134 000. 134 000. 134 000. 134 000. 134 000. 134 000. 134 000. 134 00. 134 00. 135 00. 137 120 00. 137 | % 9.53 [2.11, 43.03] % 1.63 [0.39, 6.81] % 1.63 [0.39, 6.81] % 1.63 [0.2, 6.31] % 4.49 [2.14, 9.41] % 3.64 [2.31, 5.73] % 3.64 [0.72, 10.52] % 3.20 [0.72, 10.52] % 3.30 [0.88, 10.18] % 3.20 [0.88, 10.18] % 3.20 [0.88, 10.18] % 3.20 [1.27, 12, 51] % 4.51 [2.37, 8.60] % 4.51 [2.54, 8.88] | cM1 cM0 Odds Ratio |
| E. Agger.2021 Hiyoshi.2019 Iwasa.2021 Kawai.2021 Ogawa.2016 Total (95% CI) Total events Heterogeneity: Chi?- Test for overall effec D Study or Subgroup Abe.2022 Fujita.2009 Kim.2018 Lim.2013 Malakom.2019 Ogawa.2016 Sugihara.2006 Wu.2007 | $\begin{array}{cccc} 5 & 13 \\ 3 & 11 \\ 0 & 12 \\ 15 & 32 \end{array}$ | LI (-) Events Total Weigl 134 0.21); P = 32% 0001) Events Total Weigl 135 69 22 13 135 14.89 13 135 14.89 13 14.89 17 13 14.89 17 14 16 17 17 17 17 17 17 17 17 17 17 | % 9.53 [2.11, 43.03] % 1.63 [0.39, 6.81] % 0.36 [0.02, 6.31] % 4.49 [2.14, 9.41] % 3.64 [2.31, 5.73] % 3.64 [2.31, 5.73] % 4.49 [2.14, 9.41] % 3.64 [2.31, 5.73] % 3.64 [2.31, 2.05] % 3.92 [1.2, 2.0, 864] % 3.92 [1.2, 8, 12.05] % 4.51 [2.37, 8.60] % 4.51 [2.37, | cM1 cM0 Odds Ratio |
| E. Agger.2021 Hiyoshi.2019 Iwasa.2021 Kawai.2021 Ogawa.2016 Total (95% CI) Total events Heterogeneity: Chi ^a : Test for overall effect D <u>Study or Subgroup</u> Abe.2022 Fujita.2009 Kim.2018 Lim.2013 Malakom.2019 Ogawa.2016 | $\begin{array}{cccc} 5 & 13 \\ 3 & 11 \\ 0 & 12 \\ 15 & 32 \end{array}$ $\begin{array}{c} 120 \\ 35 \\ = 5.90, df = 4 \ (P = \\ t \ Z = 5.59 \ (P < 0.0 \\ \hline \\ $ | 4 65 5. 17 91 17: 26 266 15: 69 420 34: 134 100. 134 000. 134 000. 134 000. 134 000. 134 000. 134 000. 134 000. 134 00. 134 00. 135 00. 137 120 00. 137 | % 9.53 [2.11, 43.03] % 1.63 [0.39, 6.81] % 0.36 [0.02, 6.31] % 4.49 [2.14, 9.41] % 3.64 [2.31, 5.73] % 3.64 [2.31, 5.73] % 4.49 [2.14, 9.41] % 3.64 [2.31, 5.73] % 3.64 [2.31, 2.05] % 3.92 [1.2, 2.0, 864] % 3.92 [1.2, 8, 12.05] % 4.51 [2.37, 8.60] % 4.51 [2.37, | cM1 cM0 Odds Ratio |
| E. Agger.2021 Hyoshi.2019 Hwasa.2021 Kawai.2021 Ogawa.2016 Total (95% CI) Total events Heterogeneity: Chi ² : Test for overall effec D <u>Study or Subgroup</u> Abe.2022 Fujita.2009 Kim.2018 Lim.2013 Malakom.2019 Ogawa.2016 Sugihara.2006 Wu.2007 Zhou.2021 Total (95% CI) | $\begin{array}{cccc} 5 & 13 \\ 3 & 11 \\ 0 & 12 \\ 15 & 32 \\ \hline \\ \textbf{120} \\ \textbf{55} \\ \textbf{590}, df = 4 \ (P = 0.0 \\ \textbf{12} \\ \textbf{559}, 0, f = 4 \ (P = 0.0 \\ \textbf{11} \\ \textbf{511} \\ \textbf{512} \\ \textbf{511} \\ \textbf{511} \\ \textbf{511} \\ \textbf{512} \\ \textbf{511} \\ \textbf{511} \\ \textbf{512} \\ \textbf{511} \\ \textbf{512} \\ 512$ | LI (-) Events Total Weigi 13 56 45 0001) Events Total Weigi 13 56 4.5 17 133 14.8 9 32 6.7 24 69 5.7 12 170 21.6 11 575 27.6 5 40 9.5 7 56 3.3 1173 100.0 | 9.53 [2.11, 43.03] 1.63 [0.39, 6.81] 0.36 [0.02, 6.31] 4.49 [2.14, 9.41] 3.64 [2.31, 5.73] 3.64 [2.31, 5.73] 4.49 [2.14, 9.41] 3.64 [2.31, 5.73] 4.57 [0.72, 10.52] 4.36 [2.20, 8.64] 3.25 [1.08, 9.80] 3.00 [0.88, 10.18] 3.92 [1.28, 12.05] 4.51 [2.37, 8.60] 4.75 [2.54, 8.86] 1.34 [0.41, 4.35] 6.22 [1.80, 21.47] | cM1 cM0 Odds Ratio |
| E, Agger.2021 Hiyoshi.2019 Iwasa.2021 Kawai.2021 Ogawa.2016 Total (95% CI) Total events Heterogeneity: ChP: Test for overall effec D <u>Study or Subgroup</u> Abe.2022 Fujita.2009 Kim.2018 Lim.2013 Malakom.2019 Ogawa.2016 Sugihara.2006 Wu.2007 Zhou.2021 Total (95% CI) Total events | | LI (-) Events Total Weind 13 56 4.5 (-) 17.3 (-) 26 266 15. (-) 420 34. 134 100. 134 (0.21); P = 32% (-) 210; P = 32% (-) 210; P = 32% (-) 210; P = 32% (-) 210; P = 32% (-) 210; P = 32% (-) 210; P | 9.53 [2.11, 43.03] 1.63 [0.39, 6.81] 0.36 [0.02, 6.31] 4.49 [2.14, 9.41] 3.64 [2.31, 5.73] 3.64 [2.31, 5.73] 4.49 [2.14, 9.41] 3.64 [2.31, 5.73] 4.57 [0.72, 10.52] 4.36 [2.20, 8.64] 3.25 [1.08, 9.80] 3.00 [0.88, 10.18] 3.92 [1.28, 12.05] 4.51 [2.37, 8.60] 4.75 [2.54, 8.86] 1.34 [0.41, 4.35] 6.22 [1.80, 21.47] | CM1 cM0 |
| E. Agger.2021 Hiyoshi.2019 Iwasa.2021 Kawai.2021 Ogawa.2016 Total events Heterogeneity: ChiP-s Test for overall effect D Study or Subgroup Abe.2022 Fujita.2009 Kim.2018 Lim.2013 Malakorn.2019 Ogawa.2016 Sugihara.2006 Wu.2007 Zhou.2021 Total events Heterogeneity: ChiP= | 5 13 3 11 0 12 15 32 120 35 = 5.90, df = 4 (P = 1 t Z = 5.59 (P < 0.0 LU (+) Events Total 5 11 30 77 14 25 8 13 16 22 72 282 118 1392 9 56 8 17 1895 2800 24.94, df = 8 (P = 0 | LI (-) Events Total Weight 134 00. 0.21); P = 32% 0001) Events Total Weight 13 56 4.5 9 32 6.7 17 133 14.8 9 32 6.7 17 133 14.8 9 32 6.7 17 7 24 6.9 17 24 6.9 17 7 56 3.3 117 300.0 115 5 40 9.5 7 56 3.3 117 100.0 15 16 3.7 17 6 3.3 17 8 0.5 16 3.3 17 9 10.0 15 16 0.5 16 0.5 17 10.0 15 16 0.5 17 10.0 15 16 0.5 16 0.5 17 10.0 15 16 0.5 17 10.0 15 16 0.5 17 10.0 15 16 0.5 17 10.0 15 16 0.5 17 10.0 15 16 0.5 16 0.5 17 10.0 16 0.5 16 0.5 17 10.0 16 0.5 17 10.0 16 0.5 17 10.0 16 0.5 17 10.0 16 0.5 17 10.0 16 0.5 17 10.0 16 0.5 16 0.5 17 10.0 16 0.5 16 0.5 17 10.0 16 0.5 17 10.0 16 0.5 17 10.0 16 0.5 17 10.0 16 0.5 17 10.0 16 0.5 17 10.0 18 0.5 18 0.5 | 9.53 [2.11, 43.03] 1.63 [0.39, 6.81] 0.36 [0.2, 6.31] 4.49 [2.14, 9.41] 3.64 [2.31, 5.73] 3.64 [2.31, 5.73] 2.76 [0.72, 10.52] 4.36 [2.20, 8.64] 3.25 [1.08, 9.80] 3.00 [0.88, 10.18] 3.92 [1.28, 12.05] 4.51 [2.37, 8.60] 4.75 [2.54, 8.88] 6.22 [1.80, 21.47] 4.02 [2.98, 5.43] | cM1 cM0 Odds Ratio |
| E, Agger.2021 Hiyoshi.2019 Iwasa.2021 Kawai.2021 Ogawa.2016 Total (95% CI) Total events Heterogeneity: ChP: Test for overall effec D <u>Study or Subgroup</u> Abe.2022 Fujita.2009 Kim.2018 Lim.2013 Malakom.2019 Ogawa.2016 Sugihara.2006 Wu.2007 Zhou.2021 Total (95% CI) Total events | 5 13 3 11 0 12 15 32 120 35 = 5.90, df = 4 (P = 1 t Z = 5.59 (P < 0.0 LU (+) Events Total 5 11 30 77 14 25 8 13 16 22 72 282 118 1392 9 56 8 17 1895 2800 24.94, df = 8 (P = 0 | LI (-) Events Total Weight 134 00. 0.21); P = 32% 0001) Events Total Weight 13 56 4.5 9 32 6.7 17 133 14.8 9 32 6.7 17 133 14.8 9 32 6.7 17 7 24 6.9 17 24 6.9 17 7 56 3.3 117 300.0 115 5 40 9.5 7 56 3.3 117 100.0 15 16 3.7 17 6 3.3 17 8 0.5 16 3.3 17 9 10.0 15 16 0.5 16 0.5 17 10.0 15 16 0.5 17 10.0 15 16 0.5 16 0.5 17 10.0 15 16 0.5 17 10.0 15 16 0.5 17 10.0 15 16 0.5 17 10.0 15 16 0.5 17 10.0 15 16 0.5 16 0.5 17 10.0 16 0.5 16 0.5 17 10.0 16 0.5 17 10.0 16 0.5 17 10.0 16 0.5 17 10.0 16 0.5 17 10.0 16 0.5 17 10.0 16 0.5 16 0.5 17 10.0 16 0.5 16 0.5 17 10.0 16 0.5 17 10.0 16 0.5 17 10.0 16 0.5 17 10.0 16 0.5 17 10.0 16 0.5 17 10.0 18 0.5 18 0.5 | 9.53 [2.11, 43.03] 1.63 [0.39, 6.81] 0.36 [0.2, 6.31] 4.49 [2.14, 9.41] 3.64 [2.31, 5.73] 3.64 [2.31, 5.73] 2.76 [0.72, 10.52] 4.36 [2.20, 8.64] 3.25 [1.08, 9.80] 3.00 [0.88, 10.18] 3.92 [1.28, 12.05] 4.51 [2.37, 8.60] 4.75 [2.54, 8.88] 6.22 [1.80, 21.47] 4.02 [2.98, 5.43] | CM1 cM0 |
| E. Agger.2021 Hiyoshi.2019 Iwasa.2021 Kawai.2021 Ogawa.2016 Total events Heterogeneity: ChiP-s Test for overall effect D Study or Subgroup Abe.2022 Fujita.2009 Kim.2018 Lim.2013 Malakorn.2019 Ogawa.2016 Sugihara.2006 Wu.2007 Zhou.2021 Total events Heterogeneity: ChiP= | 5 13 3 11 0 12 15 32 120 35 = 5.90, df = 4 (P = t Z = 5.59 (P < 0.0 LU (+) Events Total 5 11 30 77 14 25 8 13 16 22 72 282 118 1392 9 56 8 17 1895 2800 24.94, df = 8 (P = C | LI (-) Events Total Weight 134 00. 0.21); P = 32% 0001) Events Total Weight 13 56 4.5 9 32 6.7 17 133 14.8 9 32 6.7 17 133 14.8 9 32 6.7 17 7 24 6.9 17 24 6.9 17 7 56 3.3 117 300.0 115 5 40 9.5 7 56 3.3 117 100.0 15 16 3.7 17 6 3.3 17 8 0.5 16 3.3 17 9 10.0 15 16 0.5 16 0.5 17 10.0 15 16 0.5 17 10.0 15 16 0.5 16 0.5 17 10.0 15 16 0.5 17 10.0 15 16 0.5 17 10.0 15 16 0.5 17 10.0 15 16 0.5 17 10.0 15 16 0.5 16 0.5 17 10.0 16 0.5 16 0.5 17 10.0 16 0.5 17 10.0 16 0.5 17 10.0 16 0.5 17 10.0 16 0.5 17 10.0 16 0.5 17 10.0 16 0.5 16 0.5 17 10.0 16 0.5 16 0.5 17 10.0 16 0.5 17 10.0 16 0.5 17 10.0 16 0.5 17 10.0 16 0.5 17 10.0 16 0.5 17 10.0 18 0.5 18 0.5 | 9.53 [2.11, 43.03] 1.63 [0.39, 6.81] 0.36 [0.2, 6.31] 4.49 [2.14, 9.41] 3.64 [2.31, 5.73] 3.64 [2.31, 5.73] 2.76 [0.72, 10.52] 4.36 [2.20, 8.64] 3.25 [1.08, 9.80] 3.00 [0.88, 10.18] 3.92 [1.28, 12.05] 4.51 [2.37, 8.60] 4.75 [2.54, 8.88] 6.22 [1.80, 21.47] 4.02 [2.98, 5.43] | CM1 cM0 Odds Ratio M-H, Fixed, 95% CI |
| E. Agger.2021 Hiyoshi.2019 Iwasa.2021 Kawai.2021 Ogawa.2016 Total events Heterogeneity: ChiP-s Test for overall effect D Study or Subgroup Abe.2022 Fujita.2009 Kim.2018 Lim.2013 Malakorn.2019 Ogawa.2016 Sugihara.2006 Wu.2007 Zhou.2021 Total events Heterogeneity: ChiP= | 5 13 3 11 0 12 15 32 120 35 = 5.90, df = 4 (P = t Z = 5.59 (P < 0.0 LU (+) Events Total 5 11 30 77 14 25 8 13 16 22 72 282 118 1392 9 56 8 17 1895 2800 24.94, df = 8 (P = C | LI (-) Events Total Weight 134 00. 0.21); P = 32% 0001) Events Total Weight 13 56 4.5 9 32 6.7 17 133 14.8 9 32 6.7 17 133 14.8 9 32 6.7 17 7 24 6.9 17 24 6.9 17 7 56 3.3 117 300.0 115 5 40 9.5 7 56 3.3 117 100.0 15 16 3.7 17 6 3.3 17 8 0.5 16 3.3 17 9 10.0 15 16 0.5 16 0.5 17 10.0 15 16 0.5 17 10.0 15 16 0.5 16 0.5 17 10.0 15 16 0.5 17 10.0 15 16 0.5 17 10.0 15 16 0.5 17 10.0 15 16 0.5 17 10.0 15 16 0.5 16 0.5 17 10.0 16 0.5 16 0.5 17 10.0 16 0.5 17 10.0 16 0.5 17 10.0 16 0.5 17 10.0 16 0.5 17 10.0 16 0.5 17 10.0 16 0.5 16 0.5 17 10.0 16 0.5 16 0.5 17 10.0 16 0.5 17 10.0 16 0.5 17 10.0 16 0.5 17 10.0 16 0.5 17 10.0 16 0.5 17 10.0 18 0.5 18 0.5 | 9.53 [2.11, 43.03] 1.63 [0.39, 6.81] 0.36 [0.2, 6.31] 4.49 [2.14, 9.41] 3.64 [2.31, 5.73] 3.64 [2.31, 5.73] 2.76 [0.72, 10.52] 4.36 [2.20, 8.64] 3.25 [1.08, 9.80] 3.00 [0.88, 10.18] 3.92 [1.28, 12.05] 4.51 [2.37, 8.60] 4.75 [2.54, 8.88] 6.22 [1.80, 21.47] 4.02 [2.98, 5.43] | CM1 cM0 Odds Ratio M-H, Fixed, 95% CI |

depth of invasion, and the higher the probability of LPLN metastasis. Additionally, lower tumour location was also related to LPLN metastasis; however, no accurate standard was determined. Nine studies used AV =50 mm, while three studies used 40 mm as the critical level. The other 6 studies used peritoneal reentry as the cut-off. Anatomically, compared with the tumour centre located at the Ra, the lymphatic drainage of the tumour centre located at the Rb was more complex (53), In addition, the internal iliac and obturator lymph nodes were the most common LPLN metastasis pathways, which were located at the Rb (54, 55). The lower the

tumour location, the more drainage to the lateral lymph node region, and thus the higher the probability of LPLN metastasis.

Several studies showed that there was no significant difference between the sensitivity and specificity of CT and MRI in the diagnosis of LPLN metastasis (21, 23). A SA of the LPLN \geq 8 mm before CRT was a significant risk factor for LPLN metastasis; however, there was no standard for the selection of cut-off for lymph node diameter. Some studies increased the cut-off to 7 mm (25, 31, 41), which could fully delaminate transverse local recurrence (41). Fujita et al. even advanced the cut-off to 5 mm

| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | Study or Subgroup | MLNM (+) Events Total | MLNM (-) Events Total | Weight | Odds Ratio M-H, Fixed, 95% Cl | | odds Ratio Fixed, 95% Cl | | |
|---|---|---|---|---|--|--|---|--|--|
| Fullip 2008 40 119 7 91 10.8% 608[257,14.38] High 2020 9 7 31 2 47 25% 556 126 33.409 Hall 2020 9 216 12 240 17.1% 706 367,13.54 Sugmar 2016 169 223 16 229 225% 584 356 256 10.48 Sugmar 2016 193 744 26 1229 34.5% 7.39 [4.76,11.48] Total 69K 01 1386 1999 100.0% 6.20 [4.73, 8.13] Total 69K 02 1386 7 74 1999 100.0% 6.20 [4.73, 8.13] Total 69K 02 16 259 F 74 3 Heterogenetic Ch ² = 514 df = 6 (9 - 505), P = 0% Testor overall effect Z = 13.18 (P < 0.00001) B B ML Tixed 59K 01 198 5 104 29 205 11.0% 024 216 Log was 2016 75 330 9 122 11.0% 0.270 2.621 ML Start 12 12 12 36 55% 22 10.73, 6.62 Umar 2016 114 1170 25 797 35.5% 301 [193, 4.71] Mu and 2006 104 1170 25 797 35.5% 301 [193, 4.71] Mu and 2007 6 38 8 8 00 6.6% 1.390 (1.5, 2.21] Mu and 2007 8 10 16 5 14 46 97% 01 00.0% 2.52 [1.53, 3.29] Mu and 2007 8 10 16 5 14 00% 130 (1.5, 2.21) Mu and 2007 8 10 16 5 14 00% 130 (1.5, 2.21) Mu and 2007 8 10 16 5 14 09% 10.0% 2.52 [1.53, 3.29] Mu and 2007 8 10 18 5 14 09% 10.0% 2.52 [1.53, 3.29] Mu and 2007 8 10 19 57 100 57 100 20 (1.5, 7.24] Mu and 2007 8 10 19 57 100 19% 100 51 159 (1.5, 2.21) Mu and 2007 8 10 19 57 100 19% 100 51 139 (1.5, 2.21) Mu and 2007 19 5 11 44 170 25 797 35.5% 301 [1.53, 2.46] Mu trace, 595 01 (1.5, 7.24] Mu | Abe.2022 | 12 34 | 6 33 | 8.1% | 2.45 [0.79, 7.60] | | | | |
| | | | | | | | | | |
| $ \begin{array}{c c c c c c c c c c c c c c c c c c c $ | | | | | | | - | | |
| Ogewa 2016 68 223 16 229 22.5% 5.44 22.6 14.61 Signification 1386 74 26 22.3 74 26 22.5% 5.44 21.6 | | | | | 7 05 [2 67 12 64] | | | | |
| Sughara.2006 103 748 26 1229 34.8% 7.39 (4.76, 11.48) Total events 203 74 Heterogeneity: Ch ²⁺ 5 14, d ²⁺ 6 ($p = 0.53$); $f = 0.\%$ Test for overall effect Z = 13.18 ($p^2 - 0.00001$) B V(+) V(-) Odds Ratio Study of Subaroup Centrs Total Pents Total Weidtt MH.Fixed, 95% CI Abs.2022 1 6 53 2 14 29% 259 (52, 12.95) Fulls 2009 36 119 11 9 11 151 10.% 0.20 (52, 12.95) Fulls 2009 36 119 11 21 12 36 5.5% 2.20 (73, 66.2) Gamma 2016 75 330 9 122 13.5% 3.6% (1.79, 76.8] Sughara.2016 175 330 9 122 13.5% 3.6% (1.79, 76.8] Sughara.2020 35 181 5 34 0.0% 1.38 (0.50, 36.8] Vu.2007 6 36 8 6 06 0.6% 1.38 (0.50, 34.61) Total events 222 106 Heterogeneity: Ch ² = 2.6, $p = 0.28$, $p = 10.8$ Total events 222 1 0.6 5 15 5 4.7 (2.90, 1.33, 2.29) Total events 222 1 0.6 5 15 5 10 5.7 4.0% 2.24 (0.61, 7.5.8] Sughara.2006 104 1170 25 737 3.39 % 3.01 (1.93, 4.71) Zhou.2021 5 15 10 57 4.0% 2.24 (0.61, 7.5.8] Sughara.2006 104 1170 25 737 4.0% 2.24 (0.61, 7.5.8] Sughara.2007 16 36 8 0 60 6.6% 1.38 (0.50, 2.4.8, 1.6, 1.5, 4.7.9) Total events 222 1 0.6 146 10.00% 2.52 (1.93, 3.29) Total events 222 2 1.5 16 10 57 4.0% 2.14 (0.61, 7.5.8] Sughara.2006 2 41 13 5 15 6 5 15 5 10.5 0.5 2.20 VI (+) VI (-) C C Sudv Subaroop Reverts Total Events Total Weidth MH.Fixed, 0.55 CI MH.Fixed, 0.55 CI | | | | | | | | | |
| Total events 233 74 Heterogenetic, the 514 df = 61 ef = 623); $F = 0\%$ Testfor overall effect $Z = 13.19$ ($P < 0.00001$) B b b c b c c c c c c c c | | | | | | | | | |
| Helerogeneity: Chi ² = 5.14, df = 6, f = 0.53); f = 0.% Testfor overall effect Z = 13.18 (P + 0.00001) B B C V(+) V(+) V(+) V(+) C V(+) V(+ | | | | 100.0% | 6.20 [4.73, 8.13] | | • | | |
| Test for overall effect Z = 13 18 ($P < 0.00001$) B U U2 U1 NLINE ($+$) NLINE ($+$) U ($+$) U ($+$) Odds Ratio Odds Ratio Odds Ratio Study or Subgroup Events Total Events Total Weight MH. Fixed. 95% CI Abe 2022 16 53 2 2 14 2.9% 2.59 (0.52, 12.95) F (JIR 2009 36 119 11 2 11 2 36 56% 2.20 (0.73, 6.62) Km 2018 17 12 12 12 36 56% 2.00 (7.3, 6.62) Km 2010 10 117 0 2 5 77 3.59% 3.09 (1.73, 7.83) Sughara 2020 15 16 15 5 34 9.0% 1.38 (0.54), 4.511 Zhou 2021 5 16 11 0 57 4.0% 2.14 (0.81, 7.52) Total (P5% CI) 1985 1199 61 00.0% 2.52 [1.93, 3.29] C C C C C C C C | | | | | | + | | | |
| $ \begin{array}{c c c c c c c c c c c c c c c c c c c $ | | | | | | | | | |
| V(1) Odds Ratio Odds Ratio Study of Subgroup V(1) Odds Ratio Abe 2022 16 S3 2 14 2.9% 2.9% CI H-H Fixed 95% CI Abe 2022 16 S3 2 2.9% 2.9% CI H-H Fixed 95% CI Hard 170 25 77 S3.9% S3.9% <th cols<="" th=""><th>в</th><th></th><th></th><th></th><th></th><th></th><th></th></th> | <th>в</th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> | в | | | | | | | |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | | | | Weight | | | | | |
| E Agor 2021 4 6 59 22 226 11.0 % 0.72 [0.24, 2.16] Fulla 2009 36 119 11 1 21 112 36 55 % 220 [0.73, 6.62] Gagwa 2016 75 330 9 122 135 % 361 [73, 7.63] Sughara.2006 104 1170 25 797 35 9% 301 [13, 4.71] Wang 2020 35 181 5 34 9.0% 1.39 [0.50, 3.85] Wu.2007 6 38 8 8 6 6.68 % 1.39 [0.50, 3.85] Total (95% CI) 1985 1496 100.0% 2.52 [1.53, 3.29] Heterogeneity: ChF = 9.74, df = 8 ($P = 0.28$), $P = 18\%$ Test for overall effect $Z = 6.76$ ($P < 0.0001$) C Poor Well or moderate Study or Subarous For 40 (9.6000) Heterogeneity: ChF = 9.74, df = 8 ($P = 0.28$), $P = 18\%$ Test for overall effect $Z = 6.76$ ($P < 0.0001$) C Poor Well or moderate Study or Subarous For 40 (9.6000) Heterogeneity: ChF = 9.74, df = 8 ($P = 0.28$), $P = 18\%$ Total (95% CI) 1985 104 96 100.0% 2.52 [1.53, 3.29] 0.05 0.2 $v_{(+)}$ ($v_{(+)}$ ($v_{(-)}$ ($v_$ | | | | | | | - | | |
| $ \begin{array}{c c c c c c c c c c c c c c c c c c c $ | | | | | | | | | |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | | 36 119 | | | | | | | |
| Support 2006 104 11/13.3 <th 3"3.4<="" colspan="2" td="" th<=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th> | <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> | | | | | | | | |
| Wang 2020 35 181 5 34 9.0% 1.39 [150] (3.85] Wu 2007 6 36 8 60 6.5% 1.39 [151] (1411] Total (95% CI) 1985 1496 100.0% 2.52 [1.93, 3.29] Total (95% CI) 1985 1496 100.0% 2.52 [1.93, 3.29] Total (95% CI) 1985 1496 100.0% 2.52 [1.93, 3.29] Total (95% CI) 1985 1496 100.0% 2.52 [1.93, 3.29] Total (95% CI) 1985 1496 100.0% 2.52 [1.93, 3.29] Total (95% CI) 1985 1496 100.0% 2.52 [1.93, 3.29] C Odds Ratio Odds Ratio Odds Ratio Study or Subgroup Events Total Weight MH, Exed, 95% CI MH, Fixed, 95% CI Mac 2020 1 38 57 119 10.4% 20.20 (2.18) 0.05 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 | | | | | | | | | |
| $ \begin{array}{c c c c c c c c c c c c c c c c c c c $ | | | | | | _ | | | |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | | | | | | _ | | | |
| $ \begin{array}{c c c c c c c c c c c c c c c c c c c $ | | | | | | | | | |
| Total events 292 108 Heterogeneity: ChiF = 37.4 ($P = 80.20$); P= 18% 005 0.2 1 5 20 C Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Study or Subgroup Feents Total Weil or moderate Odds Ratio Odds Ratio Study or Subgroup Feents Total Years 15 62 1.5% 4.70 [0.72, 30.84] Dev.2018 4 13 5 30 3.5% 2.22 [0.49, 10.16] Hit Fixed, 95% Cl Hyoshi,2019 5 41 4 37 6.1% 1.16 [0.28, 463] Ishibe.2020 14 43 37 419 0.4% 3.56 [1.75, 7.24] Kim.2017 3 2.2 2.1 4.4 2.0% 5.23 [1.72, 7.216] Kim.2018 8 10 2.6 8.95 [1.65, 7.24] 4.16 [0.42, 3.18] 4.16 [0.42, 3.18] Komon2016 2.4 4.2 3.0% 1.06 [0.13, 7.76] 4.16 [0.42, 3.18] 4.17 [0.28, 4.63] Ogawa.2016 2.2 4.1 8.7 8.53 (8.30, 8. | | | | | | | | | |
| Test for overall effect $Z = 6.76$ (P < 0.00001) C Poor Vell or moderate Odds Ratio Study or Subaroup Events Total Events Total Weight MH, Exed , 95% C1 Abe , 2022 3 5 6 15 6 22 15% 470 (0.72, 30.84) Dev , 2018 4 13 5 300 35% 222 (0.49, 10.16) Pov , 2019 5 41 4 39 557 419 10.4% 3.566 (1.75, 72.44) Hyoshi 2019 5 41 4 39 57 419 10.4% 3.568 (1.75, 72.44) MH, Fixed , 95% C1 MH, Fixed , 95% C1 M | Total events | 292 | 108 | 100.0% | 2.52 [1.95, 5.29] | | - | | |
| $ \begin{array}{c c c c c c c c c c c c c c c c c c c $ | | | | | | 1 | 1 5 3 | | |
| Poor Well or moderate Odds Ratio Odds Ratio Study or Subproup Total Events Total Vell or moderate Odds Ratio Abe.2022 3 6 15 62 1.5% 4.70 (0.72, 30.84) Dev.2018 4 13 5 30 3.5% 2.22 (0.49, 10.16) Huits 2009 7 12 40 198 3.2% 5.53 (1.67, 18.34) Hivoshi.2019 5 41 4 37 6.1% 1.15 [0.28, 46.3] Kim.2018 2 4 2.4 2.4 3.0% 1.00 (0.13, 7.78) Kim.2018 3 9 2.1 2.29 5.23 (1.52, 27.96) 1.4% Um.2013 8 11 2.4 4.7 1.2% 5.52 (3.3, 12.75) Park 2018 6 10 2.6 8.93 (3.62, 1.3, 12.75) 1.4% Study as 2.020 4 1.7 3.5% 3.63 (0.85, 1.3.93) 1.4% Study as 2.020 4 1.7 3.5% | | | | | | V | (+) VI(-) | | |
| $ \begin{array}{c ccccccccccccccccccccccccccccccccccc$ | | | | | | | | | |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | | | | | | | Fixed, 95% Cl | | |
| Full 2009 7 1 2 40 198 3.2% 5.53 [1.67, 18.34] Hyoshi 2019 5 41 4 37 6.1% 1.15 [0.28, 463] Ishibe 2020 14 39 57 419 10.4% 3.66 [1.75, 7.24] Kim 2018 2 4 21 42 3.0% 1.00 [0.13, 7.78] Komon2018 3 4 21 42 3.0% 1.00 [0.13, 7.79] Nakanishi-2020 6 19 65 2.28 1.52, 27.96] Um.2013 8 11 2.4 71 2.9% 5.22 [1.7, 12.50] Ogawa 2016 22 41 47 3.5% 4.80 [2.33, 12.75] Park 2018 6 105 1869 14.9% 4.80 [2.33, 7.87] Wang 2020 4 17 35% 4.80 [2.33, 7.87] 90 Vang 2020 4 17 3.5% 4.80 [2.33, 7.87] 90 Vang 2020 4 47 3.5% 4.80 [2.33, 7.87] 90 Total (95% CI) 41 9 5 | | | | | 6 4.70 [0.72, 30.84 6 3.33 [0.40, 40, 40, 40] | -] | | | |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | Euiita 2009 | | | | | | | | |
| | | | | | | | | | |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | Ishibe.2020 | 14 39 | 57 4 | | 6 3.56 [1.75, 7.24 | 1] | | | |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | Kim.2007 | | | | | | + | | |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | | | 21 | | 6 1.00 [0.13, 7.78 | | | | |
| Nakarishi 2020 6 19 65 229 11.4% 11.6 [0.42, 316] Ogawa 2016 22 41 62 411 8.7% 6.52 [33, 12.75] Park 2018 6 10 26 89 3.5% 3.63 [0.95, 13.95] Seido 2019 1 12 2 44 1.2% 2.09 [0.17, 25.19] Sughara.2006 24 108 158 10.2 [2.9, 7.87] | Kim.2018 | | | | | | | | |
| Ogawa 2016 22 41 62 411 8.7% 6.52 [3.3, 12.75] Park 2018 6 10 26 89 35.5% 36.80 [35, 13.96] Sekido 2019 1 12 2 48 1.2% 2.09 [0.17, 2519] Sughara 2006 24 108 105 1869 14.9% 4.80 [2.93, 787] Wang 2019 9 29 4 47 35.5% 4.84 [1.57, 17.37] Wang 2020 4 17 36 188 7.2% 1.38 [0.43, 449] Yang 2021 3 11 18 57 7.1% 0.81 [0.18, 3.43] Yang 2021 6 14 9 59 3.34 [2.62, 4.26] Total (95% CI) 447 4570 100.0% 3.34 [2.62, 4.26] Total (95% CI) 447 4570 100.0% 3.34 [2.62, 4.26] Test for overall effect Z = 9.73 (P < 0.00001) | Komori.2018 | 3 9 | 21 2 | | | i] | | | |
| Park 2018 6 10 26 99 3.5% 3.63 [0.65, 13.95] Sekido 2019 1 12 24 12% 208 [0.7, 25.19] | Komori.2018 Lim.2013 | 3 9 8 11 | 21 2 24 | 71 2.99 | 6 5.22 [1.27, 21.50 | 6] 0] | | | |
| Sekido 2019 1 12 2 48 1.2% 2.09 [0.17, 2519] Wang 2019 9 29 4 47 3.5% 4.84 [1.33, 17.60] Wang 2020 4 17 36 18% 7.2% 1.81 [0.43, 4.49] Wung 2020 4 17 36 18% 5.23 [1.57, 17.37] Yang 2021 3 11 18 57 7.1% 0.81 [0.19, 3.43] Total (95% Cl) 447 4570 100.0% 3.34 [2.62, 4.26] | Komori.2018 Lim.2013 Nakanishi.2020 | 3 9 8 11 6 19 | 21 2 24 65 2 | 71 2.99 28 11.49 | 6 5.22 [1.27, 21.50 6 1.16 [0.42, 3.18 | 6] 0] 8] | | | |
| Wang 2019 9 29 4 47 3.5% 4.84 (1;3,17.60) Wang 2020 4 17 36 198 72% 1.88 (0.43, 4.49) Wu 2007 9 30 5 66 3.6% 52.3 (1.57, 17.37) Yang 2021 3 11 18 57 7.1% 0.81 (0.19, 3.43) Total (95% Cl) 447 4570 100.0% 3.34 (2.62, 4.26) Total (95% Cl) 447 4570 100.0% 3.34 (2.62, 4.26) Heterogeneity: Ch ² 2.3 (16.18 (P = 0.18), P = 22% 0.01 0.1 0.1 10 100 Poor Well or moderate 0 0.01 0.1 0.1 0.01 0.1 0.01 0.1 0.01 0.1 0.01 0.1 0.01 0.1 0.01 0.1 0.01 0.1 0.01 0.1 0.01 0.1 0.01 0.1 0.01 0.1 0.01 0.1 0.01 0.1 0.01 0.1 0.01 0.1 0.01 0.1 0.01 0.1 0.01 0.1 0.01 0.01 0.01 | Komori.2018 Lim.2013 Nakanishi.2020 Ogawa.2016 | 3 9 8 11 6 19 22 41 | 21 2 24 65 2 62 4 | 71 2.99 28 11.49 11 8.79 | 6 5.22 [1.27, 21.50 6 1.16 [0.42, 3.18 6 6.52 [3.33, 12.75 | 5] 0] 8] 5] | | | |
| Wang 2020 4 17 36 198 7.2% 1.38 [0.43, 49] Wu 2007 9 30 5 66 3.6% 5.23 [1.57, 17.37] Yang 2021 3 11 18 57 7.1% 0.81 [0.19, 3.43] Zhou 2021 6 14 9 59 3.3% 4.17 [1.16, 14.90] Total (95% CI) 447 4570 100.0% 3.34 [2.62, 4.26] Heterogeneity: Chi ² = 23.21, df = 18 (P = 0.18); P = 22% 0.01 0.1 1 10 Test for overail effect Z = 9.73 (P < 0.00001) | Komori.2018 Lim.2013 Nakanishi.2020 Ogawa.2016 Park.2018 Sekido.2019 | 3 9 8 11 6 19 22 41 6 10 1 12 | 21 2 24 65 2 62 4 26 2 | 71 2.99 28 11.49 11 8.79 89 3.59 48 1.29 | 6 5.22 [1.27, 21.50 6 1.16 [0.42, 3.18 6 6.52 [3.33, 12.75 6 3.63 [0.95, 13.95 6 2.09 [0.17, 25.19 | 6] 0] 6] 6] 9] | | | |
| Wu.2007 9 30 5 66 3.6% 5.23 [1.57, 17.37] Yang.2021 3 11 18 57 71% 0.81 [0.19, 3.43] Total (95% Cl) 447 4570 100.0% 3.34 [2.62, 4.26] Total (95% Cl) 447 4570 100.0% 3.34 [2.62, 4.26] Heterogeneity: Ch ² = 2.21, df = 18 (P = 0.18), P = 22% 0.01 0.1 1 10 100 Test for overall effect Z = 9.73 (P < 0.00001) Odds Ratio Odds Ratio Odds Ratio Odds Ratio Study or Stubgroup Events Total Weight M-H, Exed, 95% Cl M-H, Exed, 95% Cl M-H, Exed, 95% Cl Wasa 2021 2 9 18 9.3 7.0% 1.19 [0.23, 6.22] Kim 2007 2 12 2.3 3.02 [0.62, 14.63] 4.63 Lim.2013 5 6 27 76 15.2% 9.07 [1.01, 81.72] Total (95% Cl) 27 72 232 10.00% 2.90 [1.13, 7.40] 4.10 Total (95% Cl) 27 27 232 10.00% 2.90 [1.13, 7.40] 4.00 <t< td=""><td>Komori.2018 Lim.2013 Nakanishi.2020 Ogawa.2016 Park.2018 Sekido.2019 Sugihara.2006</td><td>3 9 8 11 6 19 22 41 6 10 1 12 24 108</td><td>21 2 24 65 2 62 4 26 2 105 18</td><td>71 2.99 28 11.49 11 8.79 89 3.59 48 1.29 69 14.99</td><td> 5.22 [1.27, 21.50 1.16 [0.42, 3.18 6.52 [3.33, 12.75 3.63 [0.95, 13.95 2.09 [0.17, 25.19 4.80 [2.93, 7.87 </td><td>5] 0] 5] 5] 5] 7] — —</td><td></td></t<> | Komori.2018 Lim.2013 Nakanishi.2020 Ogawa.2016 Park.2018 Sekido.2019 Sugihara.2006 | 3 9 8 11 6 19 22 41 6 10 1 12 24 108 | 21 2 24 65 2 62 4 26 2 105 18 | 71 2.99 28 11.49 11 8.79 89 3.59 48 1.29 69 14.99 | 5.22 [1.27, 21.50 1.16 [0.42, 3.18 6.52 [3.33, 12.75 3.63 [0.95, 13.95 2.09 [0.17, 25.19 4.80 [2.93, 7.87 | 5] 0] 5] 5] 5] 7] — — | | | |
| Yang, 2021 3 11 18 57 7.1% 0.81 [0.18, 3.43] Zhou.2021 6 14 9 59 3.3% 4.17 [1.16, 14.90] Total (95% CI) 447 4570 100.0% 3.34 [2.62, 4.26] Total (95% CI) 447 4570 100.0% 3.34 [2.62, 4.26] Heterogeneity: ChF = 23.21, df = 18 (P = 0.18); P = 22% 0.01 0.1 1.0 Test for overall effect Z = 9.73 (P < 0.00001) | Komori.2018 Lim.2013 Nakanishi.2020 Ogawa.2016 Park.2018 Sekido.2019 Sugihara.2006 Wang.2019 | 3 9 8 11 6 19 22 41 6 10 1 12 24 108 9 29 | 21 2 24 65 2 62 4 26 2 105 18 4 | 71 2.99 28 11.49 11 8.79 89 3.59 48 1.29 69 14.99 47 3.59 | 5.22 [1.27, 21.50 1.16 [0.42, 3.18 6.52 [3.33, 12.75 3.63 [0.95, 13.95 2.09 [0.17, 25.19 4.80 [2.93, 7.87 4.84 [1.33, 17.60 | 5] 0] 5] 6] 6] 7] 0] | | | |
| Zhou 2021 6 14 9 59 3.3% 4.17 [1.16, 14.90] Total (95% CI) 447 4570 100.0% 3.34 [2.62, 4.26] Total events 139 540 Heterogeneity: Ch ^P = 23.21, df = 18 (P = 0.18); P = 22% 0.01 0.1 1 10 100 Poor R1 R0 Odds Ratio Odds Ratio Odds Ratio Study of Subgroup Events Total Events Total Weight M-H, Exed, 95% CI M-H, Exed, 95% CI Wasa 2021 2 9 18 93 670% 11.9 (0.33, 6.22) Total events 9 67 523 100.0% 2.90 [1.13, 7.40] Total events 9 67 67 1.9 (0.30 % 0.20) 0.005 0.1 10 200 | Komori.2018 Lim.2013 Nakanishi.2020 Ogawa.2016 Park.2018 Sekido.2019 Sugihara.2006 Wang.2019 Wang.2020 | 3 9 8 11 6 19 22 41 6 10 1 12 24 108 9 29 4 17 | 21 2 24 65 2 62 4 26 2 105 18 4 36 1 | 71 2.99 28 11.49 11 8.79 89 3.59 48 1.29 69 14.99 47 3.59 98 7.29 | 5.22 [1.27, 21.50 1.16 [0.42, 3.18 6.52 [3.33, 12.75 3.63 [0.95, 13.95 2.09 [0.17, 25.19 4.80 [2.93, 7.87 4.84 [1.33, 17.60 1.38 [0.43, 4.49 | 5] 1) 5] 5] 9] | | | |
| Total events 139 540 Heterogeneity: Chi ^P = 23.21, df = 18 (P = 0.16), P = 22% 0.01 0.1 1 100 Test for overall effect Z = 9.73 (P < 0.00001) Odds Ratio Odds Ratio Study or Subgroup Fvents Total events Total events M-H, Fixed, 95% CI Masa.2021 2 9 18 93 57.0% 1.19 (0.23, 6.22) Kim.2007 2 12 22 354 27.8% 3.02 (0.62, 14.63) Lim.2013 5 6 27 76 15.2% 9.07 (1.01, 81.72) Total events 9 67 67 67 Heterogeneity: Chi ^P = 215, df = 2 (P = 0.34); P = 7% 0.005 0.1 100 | Komori.2018 Lim.2013 Nakanishi.2020 Ogawa.2016 Park.2018 Sekido.2019 Sugihara.2006 Wang.2019 Wang.2020 Wu.2007 | 3 9 8 11 6 19 22 41 6 10 1 12 24 108 9 29 4 17 9 30 | 21 2 24 65 2 62 4 26 2 105 18 4 36 1 5 | 71 2.99 28 11.49 11 8.79 89 3.59 48 1.29 69 14.99 47 3.59 98 7.29 66 3.69 | 5.22 [1.27, 21.50] 6 5.22 [1.27, 21.50] 6 1.16 [0.42, 3.18] 6 6.52 [3.33, 12.75] 5 3.63 [0.95, 13.86] 2.09 [0.17, 25.19] 6 4.80 [2.93, 7.87] 6 4.80 [2.93, 7.87] 6 4.84 [1.33, 17.60] 6 1.38 [0.43, 4.49] 5.23 [1.67, 17.37] | 5) 3) 5] 5] 5] 7] 7] 7] 7] 7] | | | |
| Total events 139 540 Heterogeneity: Chi ^P = 23.21, df = 18 (P = 0.16), P = 22% 0.01 0.1 1 100 Test for overall effect Z = 9.73 (P < 0.00001) Odds Ratio Odds Ratio Study or Subgroup Fvents Total events Total events M-H, Fixed, 95% CI Masa.2021 2 9 18 93 57.0% 1.19 (0.23, 6.22) Kim.2007 2 12 22 354 27.8% 3.02 (0.62, 14.63) Lim.2013 5 6 27 76 15.2% 9.07 (1.01, 81.72) Total events 9 67 67 67 Heterogeneity: Chi ^P = 215, df = 2 (P = 0.34); P = 7% 0.005 0.1 100 | Komori.2018 Lim.2013 Nakanishi.2020 Ogawa.2016 Park.2018 Sekido.2019 Sugihara.2006 Wang.2019 Wang.2019 Wang.2021 | 3 9 8 11 6 19 22 41 6 10 1 12 24 108 9 29 4 17 9 30 3 11 | 21 2 24 65 2 62 4 26 105 18 4 36 1 5 18 | 71 2.99 28 11.49 11 8.79 89 3.59 48 1.29 69 14.99 47 3.59 98 7.29 66 3.69 57 7.19 | 5.22 [1.27, 21.50 1.16 [0.42, 3.16 6.152 [3.33, 12.75 6.363 [0.95, 13.96 6.209 [0.17, 25.19 6.4.80 [2.93, 7.87 6.4.84 [1.33, 17.60 6.138 [0.43, 4.49 6.23 [1.57, 17.33 6.81 [0.19, 3.43 | 5) 1) 2) 3) 3) 3) 7) 7) 9) 7) 9) 7) 9) 7) 9) 7) 9) 7) 9) 71 9) 71 9) 71 90 71 90 71 71 71 71 71 71 71 71 71 71 71 71 71 | | | |
| Unit of the set for overail effect: Z = 9.73 (P < 0.00001) 0.01 0.01 0.01 Note that the set for overail effect: Z = 9.73 (P < 0.00001) Poor Well or moderate Poor Well or moderate D R1 R0 Odds Ratio Study or Subgroup Events Total Events Total Events Total 2 9 18 93 57.05 0.01 0.01 NHE Rode 95% CI MHE Rode 95% CI M-H Herode 95% CI Image: Colspan="2">M-Herode 7 C 15.2 2.2 2.54 2.76 2.00 [1.13, 7.40] Total events 9 67 100.0% 2.90 [1.13, 7.40] Total events 9 67 Heterogeneity: Chi = 2 (P = 0.34); P = 7% 0.005 0.1 1 | Komon.2018 Lim.2013 Nakanishi.2020 Ogawa.2016 Park.2018 Sekido.2019 Wang.2020 Wang.2020 Wang.2020 Yang.2021 Zhou.2021 | 3 9 8 11 6 19 22 41 6 10 1 12 24 108 9 29 4 17 9 30 3 11 6 14 | 21 2 24 65 2 62 4 26 105 18 4 36 1 5 18 9 | 71 2.99 28 11.49 11 8.79 89 3.59 48 1.29 69 14.99 47 3.59 98 7.29 66 3.69 57 7.19 59 3.39 | 6 5.22 [1.27, 21.60] 6 1.16 [0.42, 3.18 6 5.23 [3.3] [2.76] 6 3.63 [0.95, 13.96] 6 2.09 [0.17, 25.19] 6 3.63 [0.95, 13.96] 6 2.09 [0.17, 25.19] 6 4.80 [2.33, 7.87] 6 4.84 [1.33, 17.60] 6 5.23 [1.57, 17.37] 6 0.81 [0.19, 3.43] 6 4.17 [1.16, 14.90] | 5] 1] 1] 1] 1] 1] 1] 1] 1] 1] 1] 1] 1] 1] | | | |
| D R1 R0 Odds Ratio Odds Ratio Study or Subgroup Events Total Events Total Veilth H.H. Fixed, 95% CI M-H. Fixed, 95% CI wasa.2021 2 9 18 93 57.05% M-H. Fixed, 95% CI M-H. Fixed, 95% CI wasa.2021 2 12 22 354 27.8% 3.02 [0.62, 14.63] Image: Comparison of the state of the | Komon. 2018 Lim. 2013 Nakanishi. 2020 Ogawa. 2016 Park. 2018 Sekido. 2019 Sugihara. 2006 Wang. 2020 Wang. 2020 Yang. 2021 Zhou. 2021 Total (95% CI) Total events | 3 9 8 11 6 19 22 41 6 10 1 12 24 108 9 29 4 17 9 30 3 11 6 14 447 139 | 21 2 24 65 2 62 4 26 105 18 4 36 1 5 18 9 45 540 | 71 2.99 28 11.49 11 8.79 89 3.59 48 1.29 69 14.99 47 3.59 98 7.29 66 3.69 57 7.19 59 3.39 | 6 5.22 [1.27, 21.60] 6 1.16 [0.42, 3.18 6 5.23 [3.3] [2.76] 6 3.63 [0.95, 13.96] 6 2.09 [0.17, 25.19] 6 3.63 [0.95, 13.96] 6 2.09 [0.17, 25.19] 6 4.80 [2.33, 7.87] 6 4.84 [1.33, 17.60] 6 5.23 [1.57, 17.37] 6 0.81 [0.19, 3.43] 6 4.17 [1.16, 14.90] | 5] 1] 1] 1] 1] 1] 1] 1] 1] 1] 1] 1] 1] 1] | | | |
| Study or Stubgroup Event State Veriants Total Veriants Social State | Komori.2018 Lim.2013 Nakanishi.2020 Ogawa.2016 Park.2018 Sekido.2019 Sugihara.2006 Wang.2019 Wang.2020 Wang.2020 Yang.2021 Zhou.2021 Total (95% CI) Total events Heterogeneity: Chi ² = | 3 9 8 11 6 19 22 41 6 10 1 12 24 108 9 29 4 17 9 30 3 11 6 14 447 139 23.21, df = 18 (P = | 21 2 24 65 2 62 4 26 105 18 4 36 1 5 18 9 5 540 5.10 | 71 2.99 28 11.49 11 8.79 89 3.59 48 1.29 69 14.99 47 3.59 98 7.29 66 3.69 57 7.19 59 3.39 | 6 5.22 [1.27, 21.60] 6 1.16 [0.42, 3.18 6 5.23 [3.3] [2.76] 6 3.63 [0.95, 13.96] 6 2.09 [0.17, 25.19] 6 3.63 [0.95, 13.96] 6 2.09 [0.17, 25.19] 6 4.80 [2.33, 7.87] 6 4.84 [1.33, 17.60] 6 5.23 [1.57, 17.37] 6 0.81 [0.19, 3.43] 6 4.17 [1.16, 14.90] | 5) 1) 1) 1) 1) 1) 1) 1) 1) 1) 1 | + + + + + + + + + + + + + + + + + + + | | |
| Study or Stubaroup Events Total Version Total Version M-H, Fixed, 95% CI wasa.2021 2 9 18 93 57.0% 1.19 (0.23, 6.22) kim.2007 2 12 22 354 27.8% 3.02 [0.62, 14.63] Lim.2013 5 6 27 76 15.2% 9.07 [1.01, 81.72] Total (95% CI) 27 523 100.0% 2.90 [1.13, 7.40] Total events 9 67 67 0.005 0.11 10 200 | Komon.2018 Lim.2013 Nakanishi.2020 Ogawa.2016 Park.2018 Sekido.2019 Sugihara.2006 Wang.2020 Wang.2020 Wang.2020 Zhou.2021 Total (95% CI) Total events Heterogeneity: Chi ² = | 3 9 8 11 6 19 22 41 6 10 1 12 24 108 9 29 4 17 9 30 3 11 6 14 447 139 23.21, df = 18 (P = | 21 2 24 65 2 62 4 26 105 18 4 36 1 5 18 9 5 540 5.10 | 71 2.99 28 11.49 11 8.79 89 3.59 48 1.29 69 14.99 47 3.59 98 7.29 66 3.69 57 7.19 59 3.39 | 6 5.22 [1.27, 21.60] 6 1.16 [0.42, 3.18 6 5.23 [3.3] [2.76] 6 3.63 [0.95, 13.96] 6 2.09 [0.17, 25.19] 6 3.63 [0.95, 13.96] 6 2.09 [0.17, 25.19] 6 4.80 [2.33, 7.87] 6 4.84 [1.33, 17.60] 6 5.23 [1.57, 17.37] 6 0.81 [0.19, 3.43] 6 4.17 [1.16, 14.90] | 9] 9] 9] 9] 9] 9] 9] 9] 9] 9] 9] 9] 9] 9 | | | |
| Kim.2007 2 12 22 364 27.9% 3.02 [0.62, 14.63] Lim.2013 5 6 27 76 15.2% 9.07 [1.01, 81.72] Total (95% CI) 27 523 100.0% 2.90 [1.13, 7.40] Total events 9 67 Heterogenetic ChiP = 215, df = 2 (P = 0.34); P = 7% 0.005 0.1 10 200 | Komon.2018 Lim.2013 Nakanishi.2020 Ogawa.2016 Park.2018 Sekido.2019 Sugihara.2006 Wang.2020 Wang.2020 Wu.2007 Yang.2021 Zhou.2021 Total (vents Heterogeneity: Chi ² = Test for overall effect: | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | 21 2 24 2 26 2 26 2 105 18 4 36 1 5 18 9 4 5 10 5 18 9 4 5 10 5 18 9 4 5 10 5 18 9 5 10 5 18 9 5 5 10 5 18 18 18 18 18 18 18 18 18 18 | 71 2.99 28 11.49 11 8.79 89 3.59 48 1.29 69 14.99 47 3.59 98 7.29 66 3.69 57 7.19 59 3.39 | 6 522(127,216 116[042,318 6 6.52[33,127] 5 208[017,2518 6 4.80(129,787) 6 4.84(13,31760 6 1.38[043,446 5 231(57,1737 0.81[0,18,343 6 4.77[1.16,14.90 5 3.34[2.62,4.26 | 5] 1] 1] 1] 1] 1] 1] 1] 1] 1] 1 | Poor Well or moderate | | |
| Lim 2013 5 6 27 76 15.2% 9.07 [1.01, 81.72] | Komon.2018 Lim.2013 Nakanishi.2020 Ogawa.2016 Park.2018 Sekido.2019 Sugihara.2006 Wang.2019 Wang.2020 Wung.2020 Wu.2021 Zhou.2021 Total (95% CI) Total events Heterogeneity: Chi#= Test for overall effect: | 3 9 8 11 6 19 22 41 6 10 1 12 24 10 6 10 1 12 24 108 9 29 4 17 9 30 3 11 6 14 447 139 23.21, df = 18 (P= Z= 9.73 (P < 0.00 | 21 2 24 65 2 65 2 105 18 4 36 1 5 18 9 9 45 540 001) ^p = 22% | 71 2.99 28 11.49 11.8.79 89 3.55 48 1.29 69 14.99 47 3.56 98 7.29 66 3.69 57 7.19 59 3.39 70 100.09 | 5 22 (1 27, 21 62, 31 6 1 16 (0.42, 31 8 6 .52 (3.33, 12 75 3 .63 (1.95, 1.39 6 2 .09 (1.7, 251 8 4 .80 (1.23, 7.87 4 5 .23 (1.57, 17.37 0.81 (0.19, 34 3 5 .23 (1.57, 17.37 0.81 (0.19, 34 3 4 .17 (1.16, 14.90 4 3 .34 [2.62, 4.26 Odds Ratio |)))))))))))))) | °oor Well or moderate ds Ratio | | |
| Total (95% Cl) 27 523 100.0% 2.90 [1.13, 7.40] Total events 9 67 Heterogeneity: Chi ^P = 2.15, df = 2 (P = 0.34); I ^P = 7% 0.005 0.1 10 200 | Komon.2018 Lim.2013 Nakanishi.2020 Ogawa.2016 Park.2018 Sekido.2019 Sugihara.2006 Wang.2020 Wang.2020 Wang.2021 Total events Heterogeneity: Chi ^a = Test for overall effect D Study or Subgroup Iwasa.2021 | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | 21 2 24 26 2 26 2 105 18 4 36 1 5 18 9 45 540 001) = 22% 001) Events Total 18 93 | 71 2.99 28 11.49 11.87,79 89 3.59 48 1.29 69 14.99 47 3.56 98 7.29 66 3.69 57 7.19 59 3.39 70 100.05 <u>Weight 1</u> 57.0% | 5 22 (1 27, 21 62) 1 16 (0.42, 31 8 6 5.2 (3.33, 12.75 3 3.8 (0.95, 13.96) 2 0.90 (1.7, 25 18 4 0.90 (2.93, 787) 5 2.91 (5.7, 17.37 6 1.38 (0.43, 446) 5 2.3 (1 5.7, 17.37 0 81 (0.19, 3.43 6 4.71 (1.16, 14.90 3.34 [2.62, 4.26 Odds Ratio Cdds Ratio 1.1 (1.90, 2.6, 22) |)))))))))))))) | °oor Well or moderate ds Ratio | | |
| Total events 9 67 Heterogeneity: ChF = 2.15, df = 2 (P = 0.34); P = 7% Total events | Komon.2018 Lim.2013 Nakanishi.2020 Ogawa.2016 Park.2018 Sekido.2019 Sugihara.2006 Wang.2020 Wang.2020 Wang.2021 Zhou.2021 Total (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: D <u>Study or Subgroup</u> Iwasa.2021 Kim.2007 | 3 9 8 11 6 19 22 41 6 10 1 12 24 106 9 29 4 17 9 30 3 11 6 14 447 139 23.21, df = 18 (P − 2 9.73 (P < 0.00 R1 <u>Events Total</u> 2 9 2 2 12 | 21 2 24 65 2 62 4 26 105 18 4 3 6 1 5 105 8 18 9 9 45 540 001) R0 Events Total 18 93 22 354 | 71 2.99 28 11.49 11 8.77 89 3.59 48 1.29 69 14.99 47 3.59 98 7.29 69 3.49 98 7.29 63 3.69 57 7.19 59 3.39 70 100.09 Weight # | 5 22 (1 27, 21 63) 1 16 (0.42, 318 6 .52 (3.33, 12.75 3 .63 (0.95, 13.96) 2 .09 (0.17, 25.18 4 .09 (2.93, 7.87) 4 .84 (1.33, 17.60 1 .38 (0.43, 4.49 5 .23 (1.57, 17.37) 0 .61 (0.19, 3.43 4 .17 (1.16, 14.90 3 .34 (2.62, 4.26) Odds Ratio 11.9 (0.23, 6.22) 1.14 (0.23, 6.22) 1.16 (0.23, 6.22) 3 .02 (0.62, 14.63) |)))))))))))))) | °oor Well or moderate ds Ratio | | |
| Total events 9 67 Heterogeneity: ChF = 2.15, df = 2 (P = 0.34); P = 7% Total events | Komon.2018 Lim.2013 Nakanishi.2020 Ogawa.2016 Park.2018 Sekido.2019 Sugihara.2006 Wang.2020 Wang.2020 Wang.2021 Zhou.2021 Total (95% CI) Total events Heterogeneity: Chi ^a = Test for overall effect: D <u>Study or Subgroup</u> Iwasa.2021 Kim.2007 | 3 9 8 11 6 19 22 41 6 10 1 12 24 106 9 29 4 17 9 30 3 11 6 14 447 139 23.21, df = 18 (P − 2 9.73 (P < 0.00 R1 <u>Events Total</u> 2 9 2 2 12 | 21 2 24 65 2 62 4 26 105 18 4 3 6 1 5 105 8 18 9 9 45 540 001) R0 Events Total 18 93 22 354 | 71 2.99 28 11.49 11 8.77 89 3.59 48 1.29 69 14.99 47 3.59 98 7.29 69 3.49 98 7.29 63 3.69 57 7.19 59 3.39 70 100.09 Weight # | 5 22 (1 27, 21 63) 1 16 (0.42, 318 6 .52 (3.33, 12.75 3 .63 (0.95, 13.96) 2 .09 (0.17, 25.18 4 .09 (2.93, 7.87) 4 .84 (1.33, 17.60 1 .38 (0.43, 4.49 5 .23 (1.57, 17.37) 0 .61 (0.19, 3.43 4 .17 (1.16, 14.90 3 .34 (2.62, 4.26) Odds Ratio 11.9 (0.23, 6.22) 1.14 (0.23, 6.22) 1.16 (0.23, 6.22) 3 .02 (0.62, 14.63) |)))))))))))))) | °oor Well or moderate ds Ratio | | |
| Heterogeneity: Chi ² = 2.15, df = 2 (P = 0.34); i ² = 7% Tool for exceeding that T = 2.33 (P = 0.03); i ² = 7% 0.005 0.1 1 10 200 | Komon.2018 Lim.2013 Nakanishi.2020 Ogawa.2016 Park.2018 Sekido.2019 Sugihara.2006 Wang.2020 Wang.2020 Wang.2020 Zhou.2021 Total (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect D Study or Subgroup Iwasa.2021 Kim.2007 Lim.2013 | 3 9 8 11 6 19 22 41 6 10 1 12 24 106 9 29 4 17 9 300 3 11 6 14 447 139 23.21, df = 18 (P ≤ 0.00 23.21, df = 18 (P ≤ 0.00 2 = 9.73 (P ≤ 0.00 8 10 2 = 9.73 (P ≤ 0.00 8 10 2 2 9 2 12 5 6 | 21 2 24 65 2 62 4 26 105 18 4 3 6 1 5 18 9 9 45 540 001) Ro Events Total 18 9 22 354 27 76 | 71 2.99 28 11.49 11 8.73 89 3.59 48 1.22 69 14.99 47 3.59 98 7.22 66 3.69 57 7.19 59 3.33 70 100.09 Weight I 57.0% 27.8% 15.2% | 5 22 (1 27, 21 62, 16 116 (0.42, 318 6.52 (3.33, 12.75 3.63 (1.95, 1.38) 2.09 (0.17, 25.18 4.84 (1.33, 17.66 1.38 (0.42, 446 5.23 (1.57, 17.37) 0.81 (0.19, 343 4.17 (1.16, 14.90 3.34 [2.62, 4.26 Odds Ratio 1.19 (0.23, 6.22) 3.02 (0.62, 14.63) 9.07 (1.01, 81.72) |)))))))))))))) | °oor Well or moderate ds Ratio | | |
| Test for suproll offert 7 = 2.32 /B = 0.02 | Komon.2018 Lim.2013 Nakanishi.2020 Ogawa.2016 Park.2018 Sekido.2019 Sugihara.2006 Wang.2020 Wang.2021 Zhou.2021 Total (95% CI) Total events Heterogeneiky: Chi ² = Test for overall effect: Study or Subgroup Imas.2027 Lim.2013 Total (95% CI) | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | 21 2 24 26 2 2 105 18 4 36 1 5 18 9 45 540 001) Events Total 18 93 22 354 27 76 523 | 71 2.99 28 11.49 11 8.73 89 3.59 48 1.22 69 14.99 47 3.59 98 7.22 66 3.69 57 7.19 59 3.33 70 100.09 Weight I 57.0% 27.8% 15.2% | 5 22 (1 27, 21 62, 16 116 (0.42, 318 6.52 (3.33, 12.75 3.63 (1.95, 1.38) 2.09 (0.17, 25.18 4.84 (1.33, 17.66 1.38 (0.42, 446 5.23 (1.57, 17.37) 0.81 (0.19, 343 4.17 (1.16, 14.90 3.34 [2.62, 4.26 Odds Ratio 1.19 (0.23, 6.22) 3.02 (0.62, 14.63) 9.07 (1.01, 81.72) |)))))))))))))) | °oor Well or moderate ds Ratio | | |
| KI KU | Komon.2018 Lim.2013 Nakanishi.2020 Ogawa.2016 Park.2018 Sekido.2019 Sugihara.2006 Wang.2019 Wang.2020 Wu.2020 Yang.2020 Yang.2021 Zhou.2021 Total (95% CI) Total events D Study or Subgroup Iwasa.2021 Kim.2007 Lim.2013 Total (95% CI) Total events | 3 9 8 11 6 19 22 41 6 10 1 12 24 108 9 29 4 17 9 30 3 11 6 14 447 139 23.21, df = 18 (P= Z 9,73 (P < 0.00 R1 Events Total 2 9 2 12 5 6 8 7 9 | 21 2 24 65 2 62 4 26 4 105 18 4 36 1 5 540 5 540 5 540 5 540 5 540 5 18 9 5 540 5 18 9 5 18 9 5 18 9 5 18 9 5 22 354 27 76 523 67 | 71 2.99 28 11.49 11 8.73 89 3.59 48 1.22 69 14.99 47 3.59 98 7.22 66 3.69 57 7.19 59 3.33 70 100.09 Weight I 57.0% 27.8% 15.2% | 6 5.22 (1.2.7, 21.63 6 1.16 (0.42, 316 6 6.52 (3.33, 12.75 6 3.63 (0.65, 1.36) 2.08 (0.17, 25.18 4.84 (1.33, 17.60 5.23 (1.57, 17.37 6 1.38 (0.43, 446) 5.23 (1.57, 17.37 0.61 (0.19, 3.43 4.17 (1.16, 14.90 6 3.34 [2.62, 4.26 Odds Ratio H. Fixed, 95% (1) 1.19 (0.23, 6.22) 3.02 (0.62, 14.63) 9.07 [1.01, 81, 72] 2.90 [1.13, 7.40] | 9] 9] 9] 9] 9] 9] 9] 9] 9] 9] 9] 9] 9] 9 | ds Ratio xxed, 95% Cl | | |
| | Komori.2018 Lim.2013 Nakanishi.2020 Oʻgava.2016 Park.2018 Sekido.2019 Sugihara.2006 Wang.2020 Wang.2020 Wang.2021 Zhou.2021 Total (95% CI) Total events Heterogeneity: Chi ^a = Test for overall effect: D Study or Subgroup Iwasa.2021 Kim.2007 Lim.2013 Total events Heterogeneity: Chi ^a | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | 21 2 24 26 2 2 105 18 4 36 1 5 105 18 4 36 1 5 18 9 45 540 001) R0 Events Total 18 93 22 354 27 76 523 0.34); ² = 7% | 71 2.99 28 11.49 11 8.73 89 3.59 48 1.22 69 14.99 47 3.59 98 7.22 66 3.69 57 7.19 59 3.33 70 100.09 Weight I 57.0% 27.8% 15.2% | 6 5.22 (1.2.7, 21.63 6 1.16 (0.42, 316 6 6.52 (3.33, 12.75 6 3.63 (0.65, 1.36) 2.08 (0.17, 25.18 4.84 (1.33, 17.60 5.23 (1.57, 17.37 6 1.38 (0.43, 446) 5.23 (1.57, 17.37 0.61 (0.19, 3.43 4.17 (1.16, 14.90 6 3.34 [2.62, 4.26 Odds Ratio H. Fixed, 95% (1) 1.19 (0.23, 6.22) 3.02 (0.62, 14.63) 9.07 [1.01, 81, 72] 2.90 [1.13, 7.40] |)))))))))))))) | evor Well or moderate | | |

(23, 29). More researchers predicted the risk of LPLN metastasis through the ROC curve area, and the size of the lymph node corresponding to the largest area was selected as the cut-off (26, 27, 32, 52). Although the standard is not unified, most studies set the critical value of lymph node size before nCRT as 8 mm. The results of our data analysis support that a pre-CRT SA of LPLN \geq 8 mm is a significant risk factor for LPLN metastasis. Similarly, our results also showed that the SA of LPLN \geq 5 mm after nCRT was significantly related to LPLN metastasis. Most of the included articles suggested 5 mm as the cut-off, except that Kawai et al. suggested 8 mm (17) and Zhou et al. suggested 7 mm (15), because 100% sensitivity was observed for a size \geq 5 mm after nCRT to

predict LPLN metastasis (18). Therefore, a SA \geq 5 mm in the remaining LPLN after nCRT should be one of the clear signals of LPLN metastasis. In general, both before and after nCRT, our results showed that LPLN enlargement was significantly related to LPLN metastasis. In addition to lymph node enlargement, the specific imaging features of lymph node metastasis are also very important. Notably, the morphology of lymph nodes on MRI showing irregular boundaries and mixed signal intensity is often suggestive of LPLN metastasis, and our analysis of results also demonstrates that the irregular boundaries of LPLN is risk factor for lateral lymph node metastasis, which is consistent with previous research results (56). Some studies even found that it could improve

FIGURE



the prediction ability of MRI for LPLN metastasis in place of lymph node size (57). Regarding the depth of cancer invasion, Wang et al. considered it an important indicator for LPLN metastasis assessed by preoperative diagnostic imaging (28). Our results showed that patients with cT4 stage were more likely to have LPLN metastasis than those with cT2-3 stage; equally, patients with cM1 stage were more prone to have LPLN metastasis than patients with cM0. Rectal lymphatic vessels arise from the lamina propria of the rectal mucosa in anatomy; thus, the percentage of lymph node metastasis is approximately 8-15% in patients with early RC (58, 59). When the tumour invades the submucosa, cancer cells have more opportunity to spread through the lymphatic vessels, leading to LPLN metastasis. In addition, the deeper the infiltration, the higher the probability of LPLN metastasis. The overall study shows that the risk of LPLN metastasis is closely related to the clinical stage of the tumour, and the later the clinical stage of the tumour, the higher the risk of LPLN metastasis.

Current studies have shown that lymphatic, venous and perineural invasions are risk factors for LR of RC, with 1 recurrence confirmed by histopathological examination in every 4 to 5 patients (60, 61). Our results showed that LI (including MLNM) and VI were strong predictors of LPLN metastasis. It is clear that LI (including MLNM) and VI indicate a later stage of the tumor and an increased risk of lateral lymph node metastasis. In addition, compared with well or moderate differentiation, our results showed that poor differentiation was a risk factor for LPLN metastasis. It is obvious that poorly differentiated carcinoma has stronger invasive and metastatic abilities and is more likely to have distant metastasis, so poorly differentiated RC is more likely to have lateral lymph node metastasis. Echoing previous reports, compared with tubular and papillary adenocarcinoma, mucinous and signet ring adenocarcinoma that did not respond to radiotherapy had a higher probability of LPLN metastasis (3, 7, 62). In addition, we also analysed whether a positive circumferential margin was a risk factor for LPLN metastasis. The results showed that a positive circumferential margin (R1) was also a risk factor for LPLN metastasis. It was obvious that RC patients with R1 were often in a later clinical stage and more likely to develop lateral lymph node metastasis.

Currently, more methods of predicting LPLN metastasis are being developed. However, it is necessary to explore better techniques to help surgeons make more accurate judgements. Dev et al. proposed a risk stratification nomogram based on important predictors of LPLN metastasis to comprehensively evaluate and guide treatment (20). Miyake et al. used a novel one-step nucleic acid amplification (OSNA) assay to calculate LPLN metastasis targeting lymph node micrometastasis with 100% sensitivity and 86% specificity, which was significantly higher than that of CT and MRI (63). Iwasa et al. proved that the presence of the middle rectal artery (MRA) assessed by ceMRI could accurately predict bilateral LPLN metastasis (including micrometastasis) (25). Abe et al. proved that extramural venous invasion on MRI (MRI-EMVI) was independently related to LPLN metastasis and proposed that it could more accurately predict LPLN metastasis combined with lymph node size (12). As we mentioned above, treatments for LPLN metastasis of LRC differ between eastern and western countries. We supported that combining the advantages of both treatments, developing strengths and avoiding weaknesses, may achieve an unprecedented effect. We recommend patients with the following risk factors: Age <60 years, female, elevated CEA level, large tumor volume, low distance from anal margin, enlarged lymph nodes with irregular enhancement (especially SA of LPLN ≥8 mm before nCRT, SA of LPLN \geq 5 mm after nCRT), pT 3 - 4, pN 2 can be given priority to comprehensive treatment including lateral lymph node dissection. Other low-risk factors can be carefully performed lateral lymph node dissection to avoid complications and trauma caused by lateral lymph node dissection. There were some limitations in our study. First, most of the articles included were retrospective studies. Second, except for two articles from Western countries (America and Switzerland), the rest were from Eastern countries, which might have caused our research to be slightly biased towards the Eastern perspective.

5 Conclusion

Our studies proved that female sex, age <60 years, pretherapeutic CEA level >5 ng/ml, cT4, cM1, distance of the tumour from the AV <50 mm, tumour centre located Rb, SA of



Rb. (I) Tumor size ≥50 mm. (J) cT. (K) cM. (L) LI. (M) MLNM. (N) VI. (O) Differentiation. (P) CRM.

LPLN ≥ 8 mm before nCRT, SA of LPLN ≥ 5 mm after nCRT, border irregularity of LPLN, tumour size ≥ 50 mm, pT3-4, pN2, MLNM, LI, VI, CRM (+) and poor differentiation were risk factors for LPLN metastasis. In conclusion, although lateral lymph node dissection can reduce the local recurrence rate, increase the number of lymph nodes harvested, and achieve more accurate assessment of rectal cancer, it also has the risk of increasing surgery-related complications. Whether to perform lateral lymph node dissection in clinical practice can be judged in combination with the above risk factors so that patients with rectal cancer who need lateral lymph node dissection can be accurately screened out to reduce the risk of unnecessary surgical trauma. According to the risk factors of lateral lymph node metastasis, we can adopt different comprehensive treatment strategies. High-risk patients can perform lateral lymph node dissection to effectively reduce local recurrence; In low-risk patients, we can avoid overtreatment, reduce complications and trauma caused by lateral lymph node dissection, and maximize patient survival and quality of life.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Author contributions

D-xZ, ZY, and LT acquisition of data, analysis and interpretation of data, and drafting the article; M-nR and Z-lL collect and organize data, and revising the article; J-wX conception and design of the study, and critical revision. All authors contributed to the article and approved the submitted version.

Funding

This study was supported by National Natural Science Foundation of China, NO.30700773, NO.81070378 and NO.81270561; Special Research Fund for the First Affiliated Hospital of Chengdu Medical College, NO.CYFY2019YB08; and High-level Talents Introduction Fund for the First Affiliated Hospital of Chengdu Medical College, NO.CYFY2018GQ17. the

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* (2021) 71(3):209–49. doi: 10.3322/caac.21660

2. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. *Gut* (2017) 66(4):683–91. doi: 10.1136/gutjnl-2015-310912

3. Takahashi T, Ueno M, Azekura K, Ohta H. Lateral node dissection and total mesorectal excision for rectal cancer. *Dis Colon Rectum* (2000) 43(10 Suppl):S59–68. doi: 10.1007/BF02237228

4. Ueno H, Yamauchi C, Hase K, Ichikura T, Mochizuki H. Clinicopathological study of intrapelvic cancer spread to the iliac area in lower rectal adenocarcinoma by serial sectioning. *Br J Surg* (1999) 86(12):1532–7. doi: 10.1046/j.1365-2168.1999.01271.x

5. Haanappel A, Kroon HM, Schaap DP, Bedrikovetski S, Dudi-Venkata NN, Lee HX, et al. Lateral lymph node metastases in locally advanced low rectal cancers may not be treated effectively with neoadjuvant (Chemo)Radiotherapy only. *Front Oncol* (2019) 9:1355. doi: 10.3389/fonc.2019.01355

6. Kim TH, Jeong SY, Choi DH, Kim DY, Jung KH, Moon SH, et al. Lateral lymph node metastasis is a major cause of locoregional recurrence in rectal cancer treated with preoperative chemoradiotherapy and curative resection. *Ann Surg Oncol* (2008) 15 (3):729–37. doi: 10.1245/s10434-007-9696-x

7. Sugihara K, Kobayashi H, Kato T, Mori T, Mochizuki H, Kameoka S, et al. Indication and benefit of pelvic sidewall dissection for rectal cancer. *Dis Colon Rectum* (2006) 49(11):1663–72. doi: 10.1007/s10350-006-0714-z

8. Fujita S, Akasu T, Mizusawa J, Saito N, Kinugasa Y, Kanemitsu Y, et al. Postoperative morbidity and mortality after mesorectal excision with and without lateral lymph node dissection for clinical stage II or stage III lower rectal cancer (JCOG0212): results from a multicentre, randomised controlled, non-inferiority trial. *Lancet Oncol* (2012) 13(6):616–21. doi: 10.1016/S1470-2045(12)70158-4

9. Yano H, Moran BJ. The incidence of lateral pelvic side-wall nodal involvement in low rectal cancer may be similar in Japan and the West. *Br J Surg* (2008) 95(1):33–49. doi: 10.1002/bjs.6061

Key Project of Sichuan Provincial Department of Science and Technology Applied Basic Research Program, China (NO. 2022NSFSC0050).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2023.1219608/ full#supplementary-material

10. Ueno M, Oya M, Azekura K, Yamaguchi T, Muto T. Incidence and prognostic significance of lateral lymph node metastasis in patients with advanced low rectal cancer. *Br J Surg* (2005) 92(6):756–63. doi: 10.1002/bjs.4975

11. Kusters M, Wallner C, Lange MM, DeRuiter MC, van de Velde CJ, Moriya Y, et al. Origin of presacral local recurrence after rectal cancer treatment. *Br J Surg* (2010) 97(10):1582–7. doi: 10.1002/bjs.7180

12. Abe T, Yasui M, Imamura H, Matsuda C, Nishimura J, Haraguchi N, et al. Combination of extramural venous invasion and lateral lymph node size detected with magnetic resonance imaging is a reliable biomarker for lateral lymph node metastasis in patients with rectal cancer. *World J Surg Oncol* (2022) 20(1):5. doi: 10.1186/s12957-021-02464-3

13. Dev K, Veerenderkumar KV, Krishnamurthy S. Incidence and predictive model for lateral pelvic lymph node metastasis in lower rectal cancer. *Indian J Surg Oncol* (2018) 9(2):150–6. doi: 10.1007/s13193-017-0719-1

14. Agger E, Akerlund V, Ekberg O, Jorgren F, Lydrup ML, Buchwald P. Management, treatment and prognostic significance of lateral lymph node metastases in rectal cancer-a regional cohort study. *Int J Colorectal Dis* (2021) 36 (12):2707–14. doi: 10.1007/s00384-021-04018-1

15. Fujita S, Yamamoto S, Akasu T, Moriya Y. Risk factors of lateral pelvic lymph node metastasis in advanced rectal cancer. *Int J Colorectal Dis* (2009) 24(9):1085–90. doi: 10.1007/s00384-009-0704-4

16. Hiyoshi Y, Miyamoto Y, Kiyozumi Y, Eto K, Nagai Y, Iwatsuki M, et al. Risk factors and prognostic significance of lateral pelvic lymph node metastasis in advanced rectal cancer. *Int J Clin Oncol* (2020) 25(1):110–7. doi: 10.1007/s10147-019-01523-w

17. Ishibe A, Watanabe J, Suwa Y, Suzuki S, Nakagawa K, Suwa H, et al. Oncological outcomes of lateral lymph node dissection (LLND) for locally advanced rectal cancer: is LLND alone sufficient? *Int J Colorectal Dis* (2021) 36(2):293–301. doi: 10.1007/s00384-020-03760-2

18. Iwasa Y, Koyama F, Marugami N, Kuge H, Nakamoto T, Obara S, et al. The middle rectal artery detected by contrast-enhanced magnetic resonance imaging predicts lateral lymph node metastasis in lower rectal cancer. *Int J Colorectal Dis* (2021) 36(8):1677–84. doi: 10.1007/s00384-021-03887-w

19. Kawai K, Shiratori H, Hata K, Nozawa H, Tanaka T, Nishikawa T, et al. Optimal size criteria for lateral lymph node dissection after neoadjuvant chemoradiotherapy for rectal cancer. *Dis Colon Rectum* (2021) 64(3):274-83. doi: 10.1097/DCR.00000000001866

20. Kim MJ, Hur BY, Lee ES, Park B, Joo J, Kim MJ, et al. Prediction of lateral pelvic lymph node metastasis in patients with locally advanced rectal cancer with preoperative chemoradiotherapy: Focus on MR imaging findings. *PloS One* (2018) 13(4):e0195815. doi: 10.1371/journal.pone.0195815

21. Komori K, Fujita S, Mizusawa J, Kanemitsu Y, Ito M, Shiomi A, et al. Predictive factors of pathological lateral pelvic lymph node metastasis in patients without clinical lateral pelvic lymph node metastasis (clinical stage II/III): The analysis of data from the clinical trial (JCOG0212). *Eur J Surg Oncol* (2019) 45(3):336–40. doi: 10.1016/j.ejso.2018.11.016

22. Lim SB, Yu CS, Kim CW, Yoon YS, Park SH, Kim TW, et al. Clinical implication of additional selective lateral lymph node excision in patients with locally advanced rectal cancer who underwent preoperative chemoradiotherapy. *Int J Colorectal Dis* (2013) 28(12):1667–74. doi: 10.1007/s00384-013-1761-2

23. Malakorn S, Yang Y, Bednarski BK, Kaur H, You YN, Holliday EB, et al. Who should get lateral pelvic lymph node dissection after neoadjuvant chemoradiation? *Dis Colon Rectum* (2019) 62(10):1158–66. doi: 10.1097/DCR.000000000001465

24. Nakanishi R, Akiyoshi T, Toda S, Murakami Y, Taguchi S, Oba K, et al. Radiomics approach outperforms diameter criteria for predicting pathological lateral lymph node metastasis after neoadjuvant (Chemo)Radiotherapy in advanced low rectal cancer. *Ann Surg Oncol* (2020) 27(11):4273–83. doi: 10.1245/s10434-020-08974-w

25. Ogawa S, Hida J, Ike H, Kinugasa T, Ota M, Shinto E, et al. The important risk factor for lateral pelvic lymph node metastasis of lower rectal cancer is node-positive status on magnetic resonance imaging: study of the Lymph Node Committee of Japanese Society for Cancer of the Colon and Rectum. *Int J Colorectal Dis* (2016) 31 (10):1719–28. doi: 10.1007/s00384-016-2641-3

26. Oh HK, Kang SB, Lee SM, Lee SY, Ihn MH, Kim DW, et al. Neoadjuvant chemoradiotherapy affects the indications for lateral pelvic node dissection in mid/low rectal cancer with clinically suspected lateral node involvement: a multicenter retrospective cohort study. *Ann Surg Oncol* (2014) 21(7):2280–7. doi: 10.1245/ s10434-014-3559-z

27. Park BK, Lee SJ, Hur BY, Kim MJ, Chan Park S, Chang HJ, et al. Feasibility of selective lateral node dissection based on magnetic resonance imaging in rectal cancer after preoperative chemoradiotherapy. *J Surg Res* (2018) 232:227–33. doi: 10.1016/ j.jss.2018.05.047

28. Sekido Y, Nishimura J, Fujino S, Ogino T, Miyoshi N, Takahashi H, et al. Predicting lateral pelvic lymph node metastasis based on magnetic resonance imaging before and after neoadjuvant chemotherapy for patients with locally advanced lower rectal cancer. *Surg Today* (2020) 50(3):292–7. doi: 10.1007/s00595-019-01886-7

29. Wang P, Zhou S, Zhou H, Liang J, Zhou Z. Evaluating predictive factors for determining the presence of lateral pelvic node metastasis in rectal cancer patients following neoadjuvant chemoradiotherapy. *Colorectal Dis* (2019) 21(7):791–6. doi: 10.1111/codi.14595

30. Wang L, HIrano Y, Heng G, Ishii T, Kondo H, Hara K, et al. The significance of lateral lymph node metastasis in low rectal cancer: a propensity score matching study. *J Gastrointest Surg* (2021) 25(7):1866–74. doi: 10.1007/s11605-020-04825-x

31. Wu ZY, Wan J, Li JH, Zhao G, Yao Y, Du JL, et al. Prognostic value of lateral lymph node metastasis for advanced low rectal cancer. *World J Gastroenterol* (2007) 13 (45):6048–52. doi: 10.3748/wjg.v13.45.6048

32. Yang X, Gu C, Hu T, Wei M, Meng W, Wang Z, et al. Indications and oncological outcomes of selective dissection for clinically suspected lateral lymph node metastasis in patients with rectal cancer based on pretreatment imaging. *Tech Coloproctol* (2021) 25(4):425–37. doi: 10.1007/s10151-020-02386-4

33. Zhou S, Jiang Y, Pei W, Liang J, Zhou Z. Risk factors and prognostic significance of lateral pelvic lymph node dissection after neoadjuvant chemoradiotherapy for rectal patients with clinically suspected lateral lymph node metastasis. *BMC Surg* (2021) 21 (1):441. doi: 10.1186/s12893-021-01443-5

34. Lo CK, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing reviewers' to authors' assessments. *BMC Med Res Methodol* (2014) 14:45. doi: 10.1186/1471-2288-14-45

35. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ* (2009) 339: b2535. doi: 10.1136/bmj.b2535

36. Garcia-Aguilar J, Cromwell JW, Marra C, Lee SH, Madoff RD, Rothenberger DA. Treatment of locally recurrent rectal cancer. *Dis Colon Rectum* (2001) 44 (12):1743–8. doi: 10.1007/BF02234449

37. Peacock O, Chang GJ. The landmark series: Management of lateral lymph nodes in locally advanced rectal cancer. *Ann Surg Oncol* (2020) 27(8):2723–31. doi: 10.1245/ s10434-020-08639-8

38. Ishihara S, Kanemitsu Y, Murono K, Otani K, Yasuda K, Nishikawa T, et al. Oncological benefit of lateral pelvic lymph node dissection for rectal cancer treated without preoperative chemoradiotherapy: a multicenter retrospective study using propensity score analysis. *Int J Colorectal Dis* (2016) 31(7):1315–21. doi: 10.1007/ s00384-016-2607-5

39. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. *N Engl J Med* (2004) 351(17):1731–40. doi: 10.1056/NEJMoa040694

40. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. *N Engl J Med* (2001) 345(9):638–46. doi: 10.1056/NEJMoa010580

41. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. *N Engl J Med* (2006) 355(11):1114–23. doi: 10.1056/NEJMoa060829

42. Ogura A, Konishi T, Cunningham C, Garcia-Aguilar J, Iversen H, Toda S, et al. Neoadjuvant (Chemo)radiotherapy with total mesorectal excision only is not sufficient to prevent lateral local recurrence in enlarged nodes: Results of the multicenter lateral node study of patients with low cT3/4 rectal cancer. *J Clin Oncol* (2019) 37(1):33–43. doi: 10.1200/JCO.18.00032

43. Akiyoshi T, Watanabe T, Miyata S, Kotake K, Muto T, Sugihara K. Japanese Society for Cancer of the C, Rectum: Results of a Japanese nationwide multiinstitutional study on lateral pelvic lymph node metastasis in low rectal cancer: is it regional or distant disease? *Ann Surg* (2012) 255(6):1129–34. doi: 10.1097/ SLA.0b013e3182565d9d

44. Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. *Int J Clin Oncol* (2015) 20(2):207–39. doi: 10.1007/s10147-015-0801-7

45. Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. *Int J Clin Oncol* (2012) 17(1):1–29. doi: 10.1007/s10147-011-0315-2

46. Akasu T, Sugihara K, Moriya Y. Male urinary and sexual functions after mesorectal excision alone or in combination with extended lateral pelvic lymph node dissection for rectal cancer. *Ann Surg Oncol* (2009) 16(10):2779–86. doi: 10.1245/s10434-009-0546-x

47. Georgiou P, Tan E, Gouvas N, Antoniou A, Brown G, Nicholls RJ, et al. Extended lymphadenectomy versus conventional surgery for rectal cancer: a metaanalysis. *Lancet Oncol* (2009) 10(11):1053–62. doi: 10.1016/S1470-2045(09)70224-4

48. Tsukamoto S, Fujita S, Ota M, Mizusawa J, Shida D, Kanemitsu Y, et al. Longterm follow-up of the randomized trial of mesorectal excision with or without lateral lymph node dissection in rectal cancer (JCOG0212). *Br J Surg* (2020) 107(5):586–94. doi: 10.1002/bjs.11513

49. Kusters M, Beets GL, van de Velde CJ, Beets-Tan RG, Marijnen CA, Rutten HJ, et al. A comparison between the treatment of low rectal cancer in Japan and the Netherlands, focusing on the patterns of local recurrence. *Ann Surg* (2009) 249(2):229–35. doi: 10.1097/SLA.0b013e318190a664

50. Williamson JS, Quyn AJ, Sagar PM. Rectal cancer lateral pelvic sidewall lymph nodes: a review of controversies and management. *Br J Surg* (2020) 107(12):1562–9. doi: 10.1002/bjs.11925

51. Kobayashi H, Mochizuki H, Kato T, Mori T, Kameoka S, Shirouzu K, et al. Outcomes of surgery alone for lower rectal cancer with and without pelvic sidewall dissection. *Dis Colon Rectum* (2009) 52(4):567-76. doi: 10.1007/DCR.0b013e3181a1d994

52. Akiyoshi T, Matsueda K, Hiratsuka M, Unno T, Nagata J, Nagasaki T, et al. Indications for lateral pelvic lymph node dissection based on magnetic resonance imaging before and after preoperative chemoradiotherapy in patients with advanced low-Rectal cancer. *Ann Surg Oncol* (2015) 22 Suppl 3:S614–620. doi: 10.1245/s10434-015-4565-5

53. Ishibe A, Ota M, Watanabe J, Suwa Y, Suzuki S, Kanazawa A, et al. Prediction of lateral pelvic lymph-node metastasis in low rectal cancer by magnetic resonance imaging. *World J Surg* (2016) 40(4):995–1001. doi: 10.1007/s00268-015-3299-7

54. Kim JH, Beets GL, Kim MJ, Kessels AG, Beets-Tan RG. High-resolution MR imaging for nodal staging in rectal cancer: are there any criteria in addition to the size? *Eur J Radiol* (2004) 52(1):78–83. doi: 10.1016/j.ejrad.2003.12.005

55. Kim SH, Chang HJ, Kim DY, Park JW, Baek JY, Kim SY, et al. What is the ideal tumor regression grading system in rectal cancer patients after preoperative chemoradiotherapy? *Cancer Res Treat* (2016) 48(3):998-1009. doi: 10.4143/crt.2015.254

56. Kusters M, Slater A, Muirhead R, Hompes R, Guy RJ, Jones OM, et al. What to do with lateral nodal disease in low locally advanced rectal cancer? A call for further reflection and research. *Dis Colon Rectum* (2017) 60(6):577–85. doi: 10.1097/DCR.00000000000834

57. Amano K, Fukuchi M, Kumamoto K, Hatano S, Ohno H, Osada H, et al. Preoperative evaluation of lateral pelvic lymph node metastasis in lower rectal cancer: Comparison of three different imaging modalities. *J Anus Rectum Colon* (2020) 4 (1):34–40. doi: 10.23922/jarc.2019-022

58. Yu SK, Chand M, Tait DM, Brown G. Magnetic resonance imaging defined mucinous rectal carcinoma is an independent imaging biomarker for poor prognosis and poor response to preoperative chemoradiotherapy. *Eur J Cancer* (2014) 50(5):920–7. doi: 10.1016/j.ejca.2013.12.007

59. Miyake Y, Mizushima T, Hata T, Takahashi H, Hanada H, Shoji H, et al. Inspection of perirectal lymph nodes by one-Step nucleic acid amplification predicts

lateral lymph node metastasis in advanced rectal cancer. Ann Surg Oncol (2017) 24 (13):3850–6. doi: 10.1245/s10434-017-6069-y

60. Huang L, Wang X, Wen C, Yang X, Song M, Chen J, et al. Hsa-miR-19a is associated with lymph metastasis and mediates the TNF-alpha induced epithelial-to-mesenchymal transition in colorectal cancer. *Sci Rep* (2015) 5:13350. doi: 10.1038/srep13350

61. Kyo K, Sameshima S, Takahashi M, Furugori T, Sawada T. Impact of autonomic nerve preservation and lateral node dissection on male urogenital function after total

mesorectal excision for lower rectal cancer. World J Surg (2006) 30(6):1014–9. doi: 10.1007/s00268-005-0050-9

62. Uyama I, Sugioka A, Matsui H, Fujita J, Komori Y, Hanai T, et al. Laparoscopic lateral node dissection with autonomic nerve preservation for advanced lower rectal cancer. *J Am Coll Surg* (2001) 193(5):579–84. doi: 10.1016/S1072-7515(01)01042-0

63. Furuhata T, Okita K, Nishidate T, Ito T, Yamaguchi H, Ueki T, et al. Clinical feasibility of laparoscopic lateral pelvic lymph node dissection following total mesorectal excision for advanced rectal cancer. *Surg Today* (2015) 45(3):310–4. doi: 10.1007/s00595-014-0906-4